Polypeptide Having The Ability To Form Connections Of Glucosyl Units In Alpha-1,3 On An Acceptor

Abstract

An isolated polypeptide having the ability to specifically form connections of glucosyl units in alpha 1,3 on an acceptor including at least one hydroxyl moiety. The polypeptide includes i) the pattern I of sequence SEQ ID NO: 1, ii) the pattern II of sequence SEQ ID NO: 2, iii) the pattern II of sequence SEQ ID NO: 3, iv) the pattern IV of sequence SEQ ID NO: 4 or derivates from one or several of said patterns. The polypeptide furthermore has the aspartic residue (D) in position 5 of the pattern II (SEQ ID NO: 2), the glutamic acid residue (E) at position 6 of the pattern III (SEQ ID NO: 3) and the aspartic acid residue (D) in position 6 of the pattern IV (SEQ ID NO: 4); and its uses.

Description

[0001] The present international application claims priority of application FR 13/01402 filed on 17 Jun. 2013, which is incorporated herein by reference.

FIELD OF THE INVENTION

[0002] The present invention relates to an isolated polypeptide having the ability to form connections of glucosyl units in alpha 1,3 on an acceptor, a polynucleotide encoding said polypeptide, its use in a production process of acceptors connected to glucosyl units in alpha 1,3, said acceptors connected to glucosyl units in alpha 1,3 and the use thereof.

PRIOR ART

[0003] Glucosyltransferases are enzymes capable of catalysing the synthesis of glucose polymers from an inexpensive substrate, such as sucrose, alone or in the presence of an acceptor of glucosyl units comprising at least one hydroxyl moiety. Within these acceptor molecules, the glucosyl units are coupled by glycosidic linkages of variable nature (.alpha.-1,6, .alpha.-1,4, .alpha.-1,2 or .alpha.-1,3).

[0004] The transglucosylases (or glucan saccharases) belonging to the family 70 of glycoside hydrolases (database: Carbohydrate Active Enzymes database and CANTAREL et al, Nucleic Acids Res., Vol. 37, p: D233-238 2009) are enzymes naturally produced by lactic acid bacteria of the genera Leuconostoc, Lactobacillus, Streptococcus or Weissela. Starting from their substrate, in particular sucrose, a renewable and cheap substrate, these enzymes catalyse the synthesis of homopolymers of glucosyl units (glucans) generally of very high molecular weight and having various structures (.alpha.-1,6/.alpha.-1,4/.alpha.-1,2 and/or .alpha.-1,3) glycosidic bonds. Also, if hydroxylated molecules are added to the reaction medium on top of the donor of glucosyl units, these enzymes may also include these molecules at the detriment of the synthesis of polymer, resulting in a wide range of oligosaccharides and/or gluco-conjugates.

[0005] From the work described in JEANES et al. (1954), describing the purification and the characterisation of glucans produced by 96 strains of Leuconostoc sp., those produced by the strain Leuconostoc mesenteroides NRRL B-742 are known (also found in L mesenteroides ATCC 13146, and since reclassified in L. citreum NRRL B-742). In effect, it produces two types of glucans: the fraction S and the fraction L.

[0006] The first glucan is composed of 50% of .alpha.-1,6 bonds in its main chain and 50% in of connections in .alpha.-1,3 (fraction S). Successive studies of the latter glucan described in JEANES & SEYMOUR (Carbonate Research, vol. 74, p: 31-40), COTE & ROBYT (Carbohydrate Research, vol. 119, p: 141-156, 1983) and REMAUD et al (J. Carbohydrate Chemistry, vol. 11 (3), 1992) showed that the latter had an original comb-like structure. More specifically, each glucosyl unit of the straight chain in this structure was branched in .alpha.-1,3 by a single glucosyl unit.

[0007] The second glucan (fraction L) produced by the same strain was composed of 73% of .alpha.-1,6 bonds and 14% of .alpha.-1,4 bonds at branching points (SEYMOUR et al., Carbohydrate Research, vol. 74, p: 41-62, 1979).

[0008] These various studies have shown that the strain L. citreum NRRL B-742 has several coding genes for transglucosylases responsible for the synthesis of glucans; which have different specificities. In the presence of extracts of this strain, it was thus possible to produce gluco-oligosaccharides which proved to have strong prebiotic properties stimulating the growth of Bifidobacterium sp. and of Lactobacillus sp. eg (CHUNG & DAY, Journal of Industrial Microbiology & Biotechnology, vol. 29, p:196-199, 2002; CHUNG & DAY, Poultry Science, vol. 83, p:1302-1306, 2004; brevet U.S. Pat. No. 7,772,212).

[0009] Now, although this strain has been known for more than fifty years, the enzymes responsible for the synthesis of these glucans are still not known. It must indeed be understood that if some of these enzymes are extracellular; others, however, remain strongly associated with the cells, including the enzyme responsible for the glucans with a high content of .alpha.-1,3 bonds (REMAUD et al., 1992). This strong association to the bacterial cells ensures that its purification and detailed characterisation could not be performed.

[0010] In 2000, Kim et al. described the cloning in E. coli of a transglucosylase resulting from this strain, called DsrB-742. The characterisation of the gene in question showed that it had 95% similarity with that of the already characterised DSR-B in L citreum NRRL B-1299 and had a polymerisation activity of the glucosyl units in .alpha.-1,6, but no specific connection activity in .alpha.-1,3.

[0011] Finally, the identification and the biochemical characterisation of the enzyme responsible for the synthesis of comb-like glucans (S) compounds of 50% of connections in .alpha.-1,3 therefore had remained totally unsuccessful so far.

DESCRIPTION OF THE DRAWINGS

[0012] FIG. 1 shows the primary structure of the reference protein .alpha.-1,3 BrS resulting from the strain L. citreum NRRL B-742.

[0013] FIG. 2 shows profiles of chromatographic analyses by HPAEC-PAD.

[0014] FIG. 3 shows an NMR profile.

[0015] FIG. 4 shows profiles of chromatographic analyses by HPAEC-PAD.

[0016] FIGS. 5 and 6 show the evolution of the rate of .alpha.-1,3 bonds depending on the sucrose/hydroxylated acceptor ratio for the whole enzyme and the truncated enzyme respectively.

[0017] FIGS. 7 and 8 show an NMR spectrum.

SUMMARY OF THE INVENTION

[0018] The inventors have now demonstrated that the synthesis of comb-like dextrans by the strain L. citreum NRRL B-742 was due to the action, not of one but of two separate transglucosylases: one responsible for the synthesis of a linear dextran, and the other responsible for connections in .alpha.-1,3 on these linear chains that act as acceptor molecules. The inventors have therefore identified a polypeptide having an enzymatic activity which had never been described before, responsible for specific connections of glucosyl units in .alpha.-1,3 on acceptor molecules, e.g. such as dextrans. Note further that the inventors were able to control the connection rate of these glycosyl units. Finally, the inventors were able to identify two orthologues of this protein sequences in two other strains of Leuconostoc.

[0019] So this is the first natural branching enzyme described for a transglucosylase which, by sequence analysis, ranks in the family GH-70. Furthermore, the synthesis of polysaccharides connected with controlled rates of glucosyl units linked in alpha-1,3 has never been described, and no such connected product existed hitherto on the market.

[0020] This type of bonds in alpha-1,3 confers resistance to the action of degradative enzymes such as glycoside hydrolases such as dextranases, glucoamylases, amylases and particularly the digestive enzymes of the human tract thus increasing the lifetime of the acceptor molecule to which they are associated, and conveying to the gluco-oligosaccharides new physicochemical and/or prebiotic properties, which prove interesting in terms of industrial applications.

[0021] Prebiotics are non-digestible food ingredients that arrive intact in the colon where they are then specifically metabolised by a certain, so-called "beneficial" category of the intestinal microbiota (human or animal). Compared with probiotics, prebiotics take precedence over the probiotics on the market for nutraceuticals, including through improved resistance to digestive barrier, potentially cheaper production costs and easier incorporation in food preparations.

[0022] In addition to their action on the intestinal flora, the so-called prebiotic molecules can also be metabolised by other commensal flora, such as skin or vaginal flora, and participate in the development of a so-called "beneficial" plant according to the same principles as those cited above.

[0023] These prebiotics include (from a perspective commercial) under the name of isomaltooligosaccharides all the glucose oligosaccharides composed mainly of .alpha.-1,6 bonds in the main chain and variable rates in .alpha.-1,4; .alpha.-1.3 and/or .alpha.-1,2 bonds. They are found naturally in various fermented products like miso, sake, soy sauce and honey. They can be industrially produced by starch hydrolysates by means of .alpha.-transglucosylases. In this case, the IMOS contain exclusively .alpha.-1,6 and .alpha.-1,4 bonds. However, these products can also be synthesised by acceptor reaction using the transglucosylases of the family GH-70. In this case, the product may also contain .alpha.-1,3 and .alpha.-1,2 bonds in addition to the .alpha.-1,6 and .alpha.-1,4 bonds, depending on the binding specificity of the glucansucrase used. These connections (.alpha.-1,3 or (.alpha.-1,2) are rare in nature, and impart to the molecules particularly interesting prebiotic properties, because they are even more difficult to digest than the other IMOS (including by certain pathogens that can partially recognise the .alpha.-1,6/.alpha.-1,4 IMOS).

[0024] The discovery made by the inventors makes it possible to consider the synthesis of a wide variety of polysaccharides having new and controlled structures and properties.

[0025] Thus, the inventors have demonstrated that the product obtained according to the reaction of their enzyme in the presence of sucrose and a linear dextran of molecular weight 1500 Da provides a polysaccharide having improved resistance to the action of digestive enzymes. The properties of this new polysaccharide as a prebiotic are therefore likely to be comparable to those of isomaltooligosaccharides or glucooligosaccharides connected in .alpha.-1,2.

[0026] Finally, such new polysaccharides may find use as prebiotic or as biopolymers, in the preparation of industrial formulations. Among the biopolymers, the polysaccharides (especially of plant origin, but also increasingly of microbial origin) can be used as texturising agents or stabilizers for various types of industrial products. An example of use of these biopolymers includes preparing readily degradable bioplastics. They could then replace the use of polymers of synthetic origin.

DETAILED DESCRIPTION OF THE INVENTION

[0027] A first object of the invention relates to an isolated polypeptide having the ability to form connections of glucosyl units in alpha 1,3 on an acceptor comprising at least one hydroxyl moiety and wherein said polypeptide comprises:

[0028] 1) The pattern I of sequence SEQ ID no 1

[0029] 2) The pattern II of sequence SEQ ID no 2

[0030] 3) The pattern III of sequence SEQ ID no 3

[0031] 4) The pattern IV of sequence SEQ ID no 4

[0032] or derivatives from one or several of said patterns; wherein said polypeptide furthermore has the aspartic residue (D) in position 5 of the pattern II (SEQ ID no 2), the glutamic acid residue (E) at position 6 of the pattern III (SEQ ID no 3) and the aspartic acid residue (D) in position 6 of the pattern IV (SEQ ID no 4).

[0033] These three amino acids can be readily identified by the skilled person, given the sequence homologies between enzymes with similar activities, such as representing the "catalytic triad" which is essential for the transglucosylase activity of the enzymes of the family GH 70 (LEEMHUIS et al, Journal of Biotechnology, vol. 163(2), p: 250-72, 2013).

[0034] In the polypeptide described above, the sequence SEQ ID no 1 is such that ADX.sub.1VANQ with X.sub.1 corresponds to F or Y; the sequence SEQ ID no 2 is such that SX.sub.2RIDAISFVD with X.sub.2 corresponds to M or I; the sequence SEQ ID no 3 is such that HX.sub.3SIVEAX.sub.4X.sub.5X.sub.6X.sub.7 with X.sub.3 corresponds to V or I, X.sub.4 corresponds to P or S, X.sub.5 corresponds to K or A, X.sub.6 corresponds to G or D, X.sub.7 corresponds to E or Q; the sequence SEQ ID no 4 is such that IVHAHDKDIQDX.sub.8VX.sub.9X.sub.10 with X.sub.8 corresponds to T or A, X.sub.9 corresponds to S or I and X.sub.10 corresponds to H or N.

[0035] Preferably, the pattern I has the sequence SEQ ID no 18 (ADFVANQ), the pattern II has the sequence SEQ ID no 19 (SMRIDAISFVD), the pattern III has the sequence SEQ ID no 20 (HISIVEAPKGE) and the pattern IV has the sequence SEQ ID no 21 (IVHAHDKDIQDTVIH).

[0036] Preferably, a polypeptide according to the invention is a polypeptide comprising the sequence SEQ ID no 5 (positions 636 to 1270 of the sequence SEQ ID no 9, domains A and C+, a part of the domain B) an orthologue, a derivative or a fragment thereof, preferably comprising the sequence SEQ ID no 6 (positions 586 to 1284 of the sequence SEQ ID no 9, comprising the entire domains A, B and C), an orthologue, a derivative or a fragment thereof.

[0037] Also advantageously, a polypeptide of the invention is a polypeptide comprising the sequence SEQ ID no 7 (positions 446 to 1356 of the sequence SEQ ID no 9, domains A, B, C and IV) an orthologue, a derivative or a fragment thereof, preferably comprising the sequence SEQ ID no 8 (positions 403 to 1606 of the sequence SEQ ID no 9, domains A, B, C, IV and V according to the homology with the transglucosylase GTF-180 of L. reuteri 180), an orthologue, a derivative or a fragment thereof.

[0038] Such a polypeptide may include the polypeptide truncated at its C-terminus (position 1313) of sequence SEQ ID no 13 (entire domains A, B and C).

[0039] Finally, a polypeptide of the invention is a polypeptide comprising or consisting of the sequence SEQ ID no 9 (entire sequence of the enzyme), an orthologue, a derivative or a fragment thereof.

[0040] The sequence SEQ ID no 9 corresponds to a polypeptide according to the invention, isolated from the strain Leuconostoc citreum NRRL B-742 (ATCC 13146), previously known as Leuconostoc mesenteroides NRRL B-742.

[0041] The term "orthologue" refers to a polypeptide having the same activity as the polypeptide of sequence SEQ ID no 9 of the strain Leuconostoc citreum NRRL742; wherein the polypeptide has an amino acid sequence that differs by at least one residue from the sequence SEQ ID no 9 and was isolated from a strain other than those mentioned above. More generally, by orthologue is meant a polypeptide having the same activity as the polypeptide of sequence SEQ ID no 9 isolated from a given bacterial strain which is derived from the same unique sequence as the polypeptide of sequence SEQ ID no 9 isolated from the strain Leuconostoc citreum NRRL B-742, which unique sequence is derived from the last common ancestor of these two strains.

[0042] Such orthologues include the sequences SEQ ID no 15 and SEQ ID no 17.

[0043] Advantageously, this orthologue was isolated from a bacterial strain belonging to the leuconostocaceae family, which includes the genera Leuconostoc, Oenococcus and Weissela Now this orthologue is preferentially isolated from a bacterial strain belonging to the genus Leuconostoc, or from the group consisting of Leuconostoc argentinum, Leuconostoc carnosum, Leuconostoc citreum, Leuconostoc gasicomitatum, inhae, Leuconostoc kimchii, and Leuconostoc pseudomesenteroides.

[0044] More simply, such an orthologue will have a sequence identity of at least 50 or 60% with the reference sequence including SEQ ID no 9, preferably at least 65%, 70%, 75%, 80% or 85%, and even more preferably at least 90%, 95%, 97%, 98% or 99% with the reference sequence.

[0045] By "derivative" is referred to a pattern or a polypeptide whose sequence has an identity percentage of at least 80%, for examples at least 85%, preferably at least 90%, and most preferably at least 95% with the reference sequence, namely a specific pattern (I, II, III or IV) or a polypeptide according to the invention, preferably with a polypeptide of sequence SEQ ID no 9.

[0046] Naturally, such a derivative of the polypeptide according to the present invention will have the enzymatic activity described above.

[0047] By "identity percentage between two polypeptide sequences" is meant the percentage of identical amino acids between two sequences to be compared, obtained with the best possible alignment of said sequences. This percentage is purely statistical and the differences between the two sequences are randomly distributed over the entire length of the amino acid sequences.

[0048] By "best possible alignment or optimal alignment" is meant the alignment for obtaining the highest percentage of identity. Sequence comparisons between two amino acid sequences are usually performed by comparing said sequences once they have been aligned in the best possible alignment; the comparison is then performed on comparison segments in order to identify and compare similarity regions. The best possible alignment to perform comparison can be performed using the local alignment algorithm developed by SMITH & WATERMAN (Ad. App. Math, vol. 2, p: 482, 1981), using the overall alignment algorithm developed by NEDDLEMAN & WUNSCH (J. Mol. Biol., vol. 48, p: 443, 1970), using the similarity method developed by PEARSON & LIPMAN (Proc. Natl. Acd. Sci. USA, vol. 85, p: 2444, 1988), using computer programs based on these algorithms (GAP, BESTFIT, BLAST P, BLAST N, FASTA, TFASTA, Genetics Computer Group, 575 Science Dr., Madison, Wis. USA), using multiple alignment algorithms MUSCLE (Edgar, Robert C., Nucleic Acids Research, vol. 32, p:1792, 2004) ou CLUSTAL (Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, Paern J, Lopez R. Nucleic acids research 2010 July, 38 Suppl: W695-9). To get the best possible alignment, we shall use preferably the BLAST program with the BLOSUM 62 matrix or the PAM matrix 30. The percentage identity is determined by comparing the two sequences aligned optimally, whereas said sequences may include additions or deletions in relation to the reference sequence so as to obtain the best possible alignment between these two sequences. The percentage identity is calculated by determining the number of identical positions between the two sequences, by dividing the number obtained by the total number of positions compared and by multiplying the result obtained 100 to generate the percentage identity between these two sequences.

[0049] By "fragment" is meant a polypeptide comprising the four units as described above and having a sequence of at least 150 amino acids, by way of example at least 450 amino acids, by way of example at least 700 amino acids, and particularly preferably a polypeptide of at least 1000 amino acids.

[0050] Preferably by fragment is meant a polypeptide comprising the domains A, B and C as the sequence SEQ ID no 13.

[0051] The terms "amino acid" and "amino acid" in the sense of the present invention correspond to any amino acid naturally present or to their residues. The amino acids may be identified either by their one-letter abbreviation, or by their three-letter abbreviation. (Asp D aspartic acid; Ile I isoleucine; Thr T threonine; Leu L Leucine; Ser S serine; Tyr tyrosine Y; Glu E glutamic acid; Phe F phenylalanine; Pro P proline; His H histidine; Gly G glycine; Lys K lysine; Ala A alanine; Arg R arginine; Cys C cystein; Trp W tryptophan; Val V valine; Gln Q glutamine; Met M methionine; Asn N asparagine). According to the present invention, the natural amino acids can be replaced by chemically modified amino acids.

[0052] The determination of the enzymatic activity of the polypeptide according to the invention can be determined by methods known to those skilled in the art, such as by use of the High Performance Liquid Chromatography Technique on reaction products with the polypeptide of the invention (MOULIS et al., J. Biol. Chem, 2006) or assay of reducing sugars by the method in dinitrosalycilic acid (SUMNER & HOWELL, 1935). More specifically, this enzymatic activity is expressed in glucansucrase units which represents the amount of enzyme which liberates one .mu.mol of fructose per minute at 30.degree. C. with a concentration of 100 gL-1 sucrose and a buffer at pH 5.2 comprising 50 mM sodium acetate. This activity is preferably determined by measuring the initial rate of production of reducing sugars (fructose) by using the DNS method (SUMNER & HOWELL). To do this, a standard range of 0-2 gL-1 of fructose is established. During kinetics, 100 .mu.l of reaction medium are then sampled and the reaction is stopped by adding an equal volume of reagent. The samples were then heated for 5 min at 95.degree. C., cooled in ice, diluted in half with water and the absorbance is read at 540 nm.

[0053] The polypeptide is "isolated" in the sense of the present invention inasmuch as it was removed from its original environment (the environment in which it is naturally located). For example, a polypeptide present naturally in a cell is not isolated. The same polypeptide separated from the other adjacent polypeptides within the cell in which it is naturally present, most commonly by a purification process, is isolated.

[0054] According to a preferred embodiment, the substrate of the polypeptide according to the invention is selected from the group consisting of .alpha.-D-glucopyranosyl fluoride, p-nitrophenyl .alpha.-D-glucopyranoside, .alpha.-D-glucopyranosyl .alpha.-L-sorofuranoside, lactulosucrose and sucrose, preferably sucrose which is the natural substrate.

[0055] The "sucrose" consists of an .alpha.-D-glucopyranosyl unit and a .beta.-D-fructofuranosyl unit associated by a link (alphal-beta2). Hydrolysis of sucrose leads to a mixture of glucose and fructose.

[0056] By "glucosyl unit" is meant the residue resulting from the cleavage of sucrose, which is temporarily associated with the enzyme in the form of a .beta.-glucosyl-enzyme and that is transferred to an acceptor comprising a hydroxyl moiety by forming a glycosidic bond with that hydroxyl moiety.

[0057] By "connection in alpha-1,3" is meant according to the invention a glucoside bond of condensation between the --OH function of the carbon located in position 1 of a first sugar and an --OH function of carbon located in position 3 of another sugar, said glucosidic bond being formed in an alpha configuration.

[0058] By "connection of glucosyl units in alpha-1,3" is meant a glucoside bond in alpha 1,3 between an acceptor according to the invention comprising at least one hydroxyl moiety and a glucosyl unit derived from the hydrolysis of sucrose by the polypeptide of the invention.

[0059] By "acceptor" according to the invention is meant any organic molecule comprising at least one free hydroxyl moiety (--OH), which acceptor is added to the reaction medium on top of the donor substrate of glucosyl units.

[0060] Such acceptor may be selected from the carbohydrate and non-carbohydrate acceptors.

[0061] Examples of non-carbohydrate acceptors include, but without being limited thereto, alcohols, polyols, phenolic compounds or still amino acids.

[0062] Examples of carbohydrate acceptors are preferably polysaccharides or more generally acceptor comprising glycosyl units.

[0063] According to a preferred embodiment, an acceptor according to the invention is a carbohydrate acceptor, preferably the latter will include glucosyl units.

[0064] Still according to a preferred embodiment, an acceptor of the invention includes polysaccharides. By polysaccharide is meant a sugar polymer containing n sugar units wherein n is an integer greater than or equal to 3.

[0065] Advantageously, these polysaccharides are composed exclusively of monomers of (glucans), and they may be linear or branched. These polysaccharides may correspond either to the .alpha.-glucans or to .beta.-glucans.

[0066] The .alpha.-glucans are glucose polymers linked together in a position. Examples of .alpha.-glucans may include dextran (more than 50% of .alpha.-1,6 bonds in the main chain), dextran branched in .alpha.-1,2 (by the action of a .alpha.-1,2 "branching sucrase"), alternan (alternate .alpha.-1,6 and .alpha.-1,3 bonds in the main chain), mutan (more than 50% of .alpha.-1,3 bonds), reuteran (.alpha.-1,4 and .alpha.-1,6 bonds in the main chain), the starch (.alpha.-1,4 and .alpha.-1,6-glucan), amylopectine (.alpha.-1, 4 and .alpha.-1,6-glucan), was glycogen (.alpha.-1,4-glucan), amylopectin (.alpha.-1,4 and .alpha.-1,6-glucan) and p (.alpha.-1,4 and .alpha.-1,6-glucan).

[0067] The .beta.-glucans are glucose polymers linked together in .beta. position. Examples of .beta.-glucans include cellulose (.beta.-1,4-glucane), curdlan (.beta.-1,3-glucane), laminarin (.beta.-1,3-et (.beta.-1,6-glucan), lentinan (.beta.-1,6:.beta.-1,3-glucan), pamylon, pleuran (.beta.-1,3-et .beta.-1,6-glucan) and zymosan (.beta.-1,3-glucan).

[0068] Now, a preferred acceptor would be an .alpha.-glucan such as amylose, starch, amylopectin, dextran, glycogen or pullulan, dextrans branched in .alpha.-1,2, alternan, mutan and reuteran.

[0069] According to a particularly preferred embodiment, an acceptor according to the invention is a dextran, a polymer whose glucosyl units are connected together by alpha 1-6 bonds. This polymer may also include branches consisting of alpha-1,2 or 1,3 or 1,4 bonds.

[0070] Dextrans used as an acceptor according to the invention have a molecular weight (MW) between 300 and 10.sup.9 Dalton (Da), preferably between 10.sup.3 and 10.sup.9 Da and even more preferably between 1000 and 210.sup.6 Da.

[0071] The advantage of the invention lies in that the polypeptide as described above is responsible for the formation of connecting glucosyl units in the alpha-1,3 position of an acceptor.

[0072] Preferably, the polypeptide according to the invention has the ability to form connections of glucosyl units in alpha 1,3 on an acceptor at a rate between 1 and 50%, preferably between 5% and 40%, and more preferably still between 10 and 40%.

[0073] Even more preferably, the polypeptide according to the invention has the ability to form connections of glucosyl units in alpha 1,3 on an acceptor at a maximum rate of 50%.

[0074] Another object of the invention concerns an isolated polynucleotide encoding a polypeptide as defined above, a fragment or a derivative thereof.

[0075] According to the invention, said polynucleotide is a DNA or RNA molecule.

[0076] By "polynucleotide" is meant broadly a DNA molecule such as for instance a cDNA (complementary DNA) or genomic or synthetic DNA, or an RNA molecule, such as a messenger RNA or synthetic RNA, as well as analogues of DNA or RNA containing non-natural nucleotide analogues, non-natural internucleotide linkages, or both. Preferably, said polynucleotide is a DNA molecule. The polynucleotides may have any topological conformation, such as linear or circular.

[0077] In a preferred embodiment of the invention, said polynucleotide is defined by the sequence SEQ ID no 10.

[0078] Another object of the invention relates to an expression vector comprising a polynucleotide as described above.

[0079] By "vector" is meant any vehicle capable of facilitating the transfer of a polynucleotide into a cell. In general, the vectors of the invention include, without limitation thereto, plasmids, cosmids, phagemids or other vehicles derived from viral or bacterial sources that have been manipulated for insertion or incorporation of a nucleotide sequence.

[0080] The choice of vectors usable in the context of the present invention is vast. They can be cloning and/or expression vectors. In general, they are known to those skilled in the art and many of them are commercially available but it is also possible to construct them or to modify them by genetic engineering techniques.

[0081] Preferably, the vectors according to the invention are plasmid vectors, also known as plasmids. The plasmids were widely described in the prior art and are well known to the skilled person (see eg SANBROOK et al., "Molecular Cloning: A Laboratory Manual," Second Edition, Cold Spring Harbor Laboratory Press, 1989). Examples include the most commonly used plasmids such as pBR322, pUC18, pUC19, pRC/CMV, SV40 and pBlueScript, pET-53-DEST, pET-55-DEST, pBAD49-DEST, pET-60-DEST. The plasmids can be designed by the use of restriction enzymes and ligation reactions or recombination systems to remove or insert specific DNA fragments. The plasmids in which the nucleotide sequences are inserted, are in the form of a single or double stranded, linear or circular DNA.

[0082] Preferably, a vector implemented in the context of the present invention contains a replication origin ensuring the initiation of replication in a producing cell and/or a host cell. It also contains the elements necessary for the expression of a polynucleotide of the invention, such as a promoter and a terminator. Examples of suitable promoter according to the invention include, but are not limited to, T7, araBAD, pLac, POX2, AOX (alcohol oxidase) promoters.

[0083] It may further comprise one or more selection gene(s) to select or identify the cells transformed or transfected with said vector (complementation of an auxotrophic mutation, a gene encoding resistance to an antibiotic . . . ). It can also comprise additional elements improving its maintenance and/or its stability in a given cell (cer sequence which promotes the monomeric maintenance of a plasmid, integration sequences into the cell genome).

[0084] The vector of the invention may optionally be associated with one or more substances improving the efficiency of transformation or transfection and/or the stability of the vector. These substances are widely documented in the literature accessible to those skilled in the art. By way of illustration but without limitation, they may be polymers, in particular cationic lipids, liposomes, nuclear proteins or neutral lipids. These substances may be used alone or in combination. One possible combination is a plasmid recombinant vector associated with cationic lipids (DOGS, DC-CHOL, spermine-chol, spermidine-chol, etc.) and neutral lipids (DOPE).

[0085] The polynucleotide, preferably the DNA molecule, in the expression vector is operatively linked to a promoter to direct the synthesis of RNA. For example, developers may be eukaryotic or prokaryotic promoters such as CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retroviruses, and mouse metallothionein-I. The expression vector also contains a ribosome binding site for initiating the translation and a transcription vector. The vector should also include enhancer sequences of the expression.

[0086] By "operably linked to a promoter" is meant the link through which a promoter is located contiguously to the polynucleotide of the invention for controlling the expression of said sequence.

[0087] The term "promoter" is well known to those skilled in the art and refers to a DNA region adjacent to a gene to which RNA polymerase binds to start the transcription.

[0088] Another object of the invention also relates to a transformed host cell comprising a vector according to the invention.

[0089] For the purposes of the present invention, such a cell consists of any cell which can be transformed or transfected by an inventive vector as described above.

[0090] The cell is called "host cell" and may be a prokaryotic cell or a eukaryotic cell.

[0091] Preferably, the host cell transformed according to the invention is a prokaryotic cell selected from the group consisting of eubacteria, archaebacteria and cyanobacteria.

[0092] The bacterial expression systems can be used in the context of the present invention. Examples of bacterial host cells include bacteria of the genera Escherichia (e.g. Escherichia coli), Pseudomonas (e.g. Pseudomonas fluorescens or Pseudomonas stutzerei), Proteus (e.g. P. mirabilis), Ralstonia (such as Ralstonia eutropha), Streptomyces, Staphylococcus (eg Streptomyces carnosus), Lactococcus (eg Lactoccocus lactis), Bacillus (eg Bacillus subtilis, Bacillus megaterium or Bacillus licheniformis), Lactobacillus or Leuconostoc etc.

[0093] More preferably, the host cell transformed according to the invention is a eukaryotic cell selected from the group consisting of animal, fungal, yeast, and plant cells.

[0094] Yeast cells are also hosts cells which can be suitable in the scope of the invention. Examples of yeast host cells which may be used include, but are not limited to, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Klyveromyces lactis, Yarrowia lipolytica, Hansenula polymorpha or Pichia pastoris.

[0095] Fungal expression systems are also conceivable within the scope of the present invention, such as Aspergillus Niger, Chrysosporium lucknowense, Aspergillus (e.g. Aspergillus oryzae, Aspergillus Niger, Aspergillus nidulans, etc.), Podospora anserina or Trichoderma reesei.

[0096] Other expression systems such as mammalian expression systems can also be used in the context of the invention, such as the NSO, CHO, BHK cell lines, transgenic systems of mammalian origin, but also the cells insect or viral expression systems such as bacteriophage M13, T7 or .lamda. or the expression systems Baculovirus

[0097] Preferably, the host cell according to the present invention is a prokaryotic cell.

[0098] The terms "transformed host cell," "transformed" and "transformation" as defined in the present invention refer to the introduction of DNA into a cell. The introduction of a polynucleotide or a vector as described in the present invention into the host cell can be effected by methods well known to those skilled in the art such as the electroporation, heat shock on competent cells, recombination, conjugation, transfection by PEI, by calcium phosphate, transfection by DEAE dextran or still electroporation.

[0099] According to another object, the invention provides a composition comprising at least one polypeptide, one polynucleotide, one vector or one host cell as described above.

[0100] Another object of the invention relates to a method of producing a polypeptide as described above, said method comprises the steps of: [0101] a) inserting a polynucleotide or a vector as described previously in a host cell; [0102] b) culturing said cell obtained in step a); and [0103] c) extracting the polypeptide of the invention from the culture obtained in step b).

[0104] Step (a) of introducing a polynucleotide or a vector as described above into the host cell is accomplished by well-known processing techniques to those skilled in the art, such as transfection, lipofection, transformation by lithium acetate, biolistic transformation, transformation by PEI, protoplast fusion, liposome transformation, transformation by Agrobacterium tumefaciens, or still viral or adenoviral infections.

[0105] Extraction of the polypeptide of the invention is made from the culture of step (b) and produced by techniques well-known to those skilled in the art. If the host organism produces the polypeptide extracellularly, the culture supernatant is recovered by centrifugation and may be directly used for implementing the syntheses of products. If the expression is intracellular, the cells are centrifuged, concentrated, then lysed by means of lysozyme and detergents or crushed ultrasonically or treated by mechanical breakage using glass beads or FRENCH press.

[0106] If necessary, the extraction can consist of a purification of the polypeptide may be performed by affinity chromatography for chelating metals such as nickel or cobalt and using a tag (label) of type "Histidine" (6 successive histidines) fused to the polypeptide sequence as described above.

[0107] Another object of the invention relates to a process for producing acceptors connected to glucosyl units in alpha 1,3 comprising a rate of connections of such glucosyl units in alpha 1,3 between 1 and 50%, said method comprising the steps of:

[0108] mixing in a reaction medium a polypeptide according to the invention, of a substrate of said polypeptide and an acceptor comprising at least one hydroxyl moiety; and

[0109] ii) incubating said mixture obtained in step i) so as to obtain the connection of glucosyl units in alpha-1,3 on said acceptor.

[0110] The term "acceptor connected to glucosyl units in alpha 1,3" according to the invention an acceptor as defined above which are attached by the action of a polypeptide according to the invention of glucosyl units derived from the hydrolysis of the substrate.

[0111] According to a preferred embodiment, an acceptor connected to glucosyl units in alpha-1,3 according to the invention is selected from the group consisting of polysaccharides, preferably glucans, in particular .alpha.-glucans such as .alpha.-1,6 glucans (eg dextran).

[0112] According to a preferred embodiment and as described above, the substrate of the polypeptide according to the invention is selected from the group consisting of .alpha.-D-glucopyranosyl fluoride, p-nitrophenyl .alpha.-D-glucopyranoside, .alpha.-D-glucopyranosyl, .alpha.-L-sorofuranoside, lactulosucrose and sucrose, preferably sucrose.

[0113] According to a preferred embodiment, the method according to the invention allows to control the rate of alpha-1,3 connections of the acceptor by directly varying the ratio between the substrate concentration and the acceptor concentration.

[0114] According to a preferred embodiment of the invention, said method is characterised in that it is intended to obtain an acceptor connected to glucosyl units in alpha 1,3 at a rate between 1% and 50%, preferably between 5 and 40% and more preferably still between 10 and 40%. This variation is possible depending on the ratio between the concentration of the substrate to that of the free hydroxyl moieties of the acceptor molecule, or the ratio between the mass concentration of the substrate to that of the acceptor in the case of dextran and sucrose.

[0115] Advantageously, the concentrations of acceptor and substrate are adjusted so as to obtain a degree of connection between 35 and 50%, preferably between 35 and 40%. Typically, this degree of connection is obtained with a ratio greater than or equal to 1.

[0116] Advantageously, the concentrations of acceptor and of substrate are adjusted so as to obtain a degree of branching between 20 and 35%. Typically, this level of connection is achieved with a ratio of between 0.5 and 1.

[0117] Advantageously still, the concentrations of acceptor and substrate are adjusted so as to obtain a degree of branching less than 20%. Typically, this rate of connection is obtained with a ratio less than 0.5.

[0118] According to the invention, the rate of connection in alpha-1,3 obtained in the context of this method is considered in relation to all the sites available on said acceptor.

[0119] According to a particular embodiment, said method according to the invention further comprises a step c) of purification of acceptor connected to glucosyl units in alpha 1,3.

[0120] Still according to a particular embodiment, the method of the invention comprises a step d) of characterisation of the acceptors connected to glucosyl units in alpha-1,3 of the invention. Such a characterisation step may be performed by various methods well-known to those skilled in the art.

[0121] By way of example, high performance liquid chromatography technique (HPLC), mass spectrometry, nuclear magnetic resonance spectrometry (NMR), chemical techniques such as methylation and acetolysis or ELISA with monoclonal antibodies specific for alpha-1,3 bonds will be used.

[0122] Another object of the invention relates to an acceptor connected to glucosyl units in alpha-1,3 obtainable by the process as described above.

[0123] Said acceptor may not be a dextran.

[0124] Also advantageously, the rate of connection of said acceptor is less than 50%, preferably less than 40%.

[0125] The present patent application is also intended to cover the various possible uses of a polypeptide, a polynucleotide, a vector, a host cell and/or a composition of the invention as described above.

[0126] Thus, another object of the invention relates to the use of a polypeptide, a polynucleotide, a vector, a host cell and/or a composition according to the invention for the production of acceptors connected to glucosyl units in alpha-1,3.

[0127] Preferably, said acceptors are connected to glucosyl unit in alpha 1,3 at a rate between 1 and 50%, preferably between 5 and 40%, and most preferably still between 10 and 40%.

[0128] This patent application is also intended to cover the various possible uses of an acceptor connected to glucosyl units in alpha-1,3 of the invention.

[0129] The invention thus relates to the use of an acceptor connected to glucosyl units in alpha-1,3 produced from a polypeptide of the invention as an agent charge, thickener, emulsifier, texturising agent and/or stabiliser in the preparation of industrial food, cosmetic, agrochemical, petrochemical and pharmaceutical formulations.

[0130] These applications consist of the use of these acceptors connected to glucosyl units in alpha-1,3 as biopolymers.

[0131] Examples of industrial formulations of the invention include without limitation bioplastics, but also the food formulations, such as bakery products, as well as formulations in the pharmaceutical sector.

[0132] Other examples of industrial formulations also include formulations for the construction, paint, paper, textile, plant protection, water treatment, oil industries.

[0133] The invention also relates to the non-therapeutic use of an acceptor connected to glucosyl units in alpha-1,3 as an agent prebiotic.

[0134] The acceptors connected to glucosyl units in alpha-1,3 produced according to the invention has the advantages of a better resistance to the digestive barrier, a better stability, potentially cheaper production costs and greater ease to be incorporated in food preparations.

[0135] Prebiotics are non-digestible food ingredients that arrive intact in the colon where they are then specifically metabolised by a certain, so-called "beneficial" category of the intestinal microbiota (human or animal).

[0136] Non-limiting examples of prebiotics effects include improved intestinal transit in animals and humans, improved absorption of minerals such as calcium, magnesium, zinc or even iron, reduced intestinal inflammation or still reduced growth of pathogens.

EXAMPLES

Example 1

Screening of New Enzymes in L. citreum NRRL B-742

[0137] After sequencing of the genome of the strain L. citreum NRRL B-742, a gene proved particularly original. Indeed the corresponding putative protein was found to have a sequence having a maximum of only 54% identity with the putative glycoside hydrolase Leuconostoc fallax KCTC 3537 whose sequence is available in the database, and referenced by the NCBI under number ZP_08312597. Now, any other protein sequence with significant identity could be identified.

[0138] This gene encodes a putative transglucosylase of 1888 amino acids, having the characteristic catalytic triad DED and the 4 conserved regions usually described in transglucosylases of family 70. The schematic representation of the protein is shown in FIG. 1 (based on the alignment of protein sequences with GTF180) with 5 domains: i) domain V (403-446 and 1356 to 1800), ii) domain IV (446-586 and 1284-1356), iii) domain A (catalytic) (636-899, 1052-1191 and 1231-1270), iv) domain B (586-636, 1191-1231 and 1270-1284) and v) domain C (899-1052). The catalytic amino acids (DED) are indicated with a star in the primary structure and are shown in bold and red in the different patterns II, III and IV.

[0139] Now, particularly original protein patterns were identified upstream and downstream of amino acids of the catalytic triad, usually in highly conserved regions (see table 1).

[0140] Due to the originality of this putative transglucosylase, it was decided to initiate cloning so as to begin its biochemical characterisation.

TABLE-US-00001 TABLE 1 Sequence Alignment of conserved regions of the catalytic heart of the new transglucosylase (called .alpha.-1,3BrS in the table) and orthologues identified (from Leuconostoc fallax KCTC3537 and Leuconostoc citreum LBAE E16) with characterised enzymes and with known specificity of links Speci- GenBank Pattern II Pattern III Pattern IV Pattern I ficity AAC6306 GtfI 449 SIRVDAVDNVD 486 HVSIVEAWSDN 559 FARAHDSEVQDLIRD 931 ADWVPDQ -1,3 3.1 [Sd] AAA8858 GtfB 1011 SIRVDAVDNVD 1048 HLSILEAWSDN 1120 FIRAHDSEVQDLIAD 1488 ADWVPDQ 8.1 [Sm] BAA2611 GtfSI 473 SIRVDAVDNVD 510 HLSILEAWSDN 583 FIRAHDSEVQDLIRD 954 ADWVPDQ 4.1 [Sm] AAU0801 GtfA 1020 SVRVDAPDNID 1056 HINILEDWNHA 1128 FVRAHDNNSQDQIQN 1508 ADWVPDQ -1,4/ 5.1 [Lr] -1,6 AAY8692 GtfO 1020 SVRVDAPDNID 1056 HINILEDWNSS 1128 FIRAHDNNSQDQIQN 1508 ADWVPDQ 3.1 [Lr] CAB6591 Asr 631 GIRVDAVDNVD 668 HLSILEDWNGK 762 FVRAHDYDAQDPIRK 1168 ADWVPDQ -1,6/ 0.2 [Lm] -1,3 ABQ8359 GtfW 748 GFRVDAADNID 785 HLVYNEGYHSG 568 FVTNHDQR-KNVINQ 1216 EDLVMNQ -4,6 7.1 [Lr] AAU0800 GtfML4 1012 GFRVDAADNID 1049 HLSYNEGYHSG 1121 FVTNHDQR-KNLINR 1479 EDIVMNQ 3.2 [Lr] ABF8583 DsrCB4 526 GIRVDAVDNVD 563 HLSILEDWSHN 636 FVRAHDSEVQTVIAQ 1001 ADWVPDQ -1,6 2.1 [Lc] CAB7656 DsrC 498 GIRVDAVDNVD 535 HLSILEDWSHN 608 FVRAHDSEVQTVIAQ 973 ADWVPDQ 5.1 [Lm] AAD1095 DsrS 547 GIRVDAVDNVD 584 HLSILEDWSHN 657 FVRAHDSEVQTVIAQ 1023 ADWVPDQ 2.1 [Lm] AAU0800 GTF180 1021 GIRVDAVDNVD 1058 HINILEDWGWD 1131 FVRAHDSNAQDQIRQ 1503 ADWVPDQ 1.1 [Lr] CAD2288 GBD- 2206 SIRIDAVDFIH 2243 HISLVEAGLDA 2317 IIHAHDKGVQEKVGA 2688 ADVVDNQ -1,2 3.1 CD.sub.2 [Lc] BrS 667 SMRIDAISFVD 704 HISIVEAPKGE 783 IVHAHDKDIQDTVIH 1182 ADFVANQ -1,3 [Lc] BrS 734 SIRIDAISFVD 771 HVSIVEASADQ 845 IVHAHDKDIQDAVSN 1232 ADYVANQ -1,3 [L. fallax] BrS 667 SMRIDAISFVD 704 HISIVEAPKGE 783 IVHAHDKDIQDTVIH 1182 ADFVANQ -1,3 [L. citreum E16]

Example 2

Production of a New Enzyme in E. coli

[0141] The gene encoding this enzyme has been cloned into several vectors (pET 53, 55, 49 and 60) commercially available from NOVAGEN or INVITROGEN, and expressed in different various of E. coli (TOP10, BL21AI, BL21 DE3 Star, Arctic Express DE3).

[0142] This cloning resulted in a consistent production of the protein. This production has helped initiate the experiments of biochemical characterisation to clarify the catalytic properties of the identified enzyme.

[0143] Simultaneously, a truncated form of the signal peptide and C-terminal, APS AC-1313 SEQ ID no 12 and SEQ ID no 13 for the nucleic and protein sequences, respectively) of the protein has been cloned and expressed in the strain of E. coli BL21 DE3 star, allowing again a significant expression of the protein; which expression has proved almost twice higher than that of the wild-type protein.

Example 3

Reaction of a Polypeptide According to the Invention with Sucrose, a Dextran-Type Acceptor and the Enzyme Object of the Invention and Analysis of the Products of this Reaction

[0144] To characterise the functional properties of this putative transglucosylase, the enzyme was first implemented on sucrose alone, a natural substrate of enzymes of the GH70 family.

[0145] Unexpectedly, the chromatographic analyses (HPAEC-PAD, HPSEC) showed that the enzyme alone is only capable of hydrolysing the substrate in equimolar amounts of glucose and fructose. Now and from sucrose alone, this enzyme showed no ability to produce polymers of glucosyl units, as well as its truncated form.

[0146] It is interesting to note that to date, bioinformatic analyses on the primary structure of the GH of the family 70 would not predict this feature (structural determinants governing the ability--or not--of a transglucosylase polymerising are not yet known).

[0147] While nothing presaged that this protein had still an activity, the latter (as well as its truncated form) was also incubated in the presence of sucrose and a linear dextran (glucan composed exclusively of .alpha.-1,6 bonds) of a molecular weight of 1500 Da.

[0148] We incubated for 16 h at 30.degree. C., enzyme in sucrose (from 25 g/L to 170 g/L) in the presence of dextrans of variable molecular weight (from 1500 Da to 210.sup.6 Da) and of varying concentration of 30 g/L to 100 g/L; the sucrose/acceptor (M/M) ratio varies depending on the desired connection rate in .alpha.-1,3. The reaction medium was buffered with a solution with final sodium acetate with 50 mM, pH 5.2. A sample at initial and final times of the reaction was conducted, heated at 95.degree. C. for 5 minutes to stop the reaction and analysed by various chromatographic (HPAEC-PAD, HPSEC) and structural (proton NMR) techniques.

[0149] More specifically, monosaccharides, disaccharides, and small oligosaccharides (degree of polymerisation less than 20) were separated and quantified by HPAEC-PAD (High Performance Anion Exchange Chromatography with Pulsed Amperometric Detection) on column Dionex CarboPac PA-100. A sodium acetate gradient of 6 to 300 mM in 36 min, containing 150 mM of sodium hydroxide used to separate glucose, fructose, sucrose, leucrose, isomaltooligosaccharides, etc. Standard ranges of 5, 10, 15 and 20 mgkg-1 of these sugars were performed to allow quantification. These samples were diluted for a total sugar concentration of 25 mgkg-1.

[0150] Analyses by HPSEC (High Performance Size Exclusion Chromatography) were used to estimate the molecular weight of oligosaccharide populations or of polymers synthesised during the reactions. The separation was done using two columns SHODEX (OH-Pack SB-805 and 802.5) arranged in series. Solutions of 1, 2.5, 5 and 10 gL-1 sucrose, fructose, maltoheptaose, Dextran 11.3 kDa, 68.4 kDa, 503 kDa, 2000 kDa served as benchmarks. The samples were diluted 10 times to reach a maximum concentration of 10 gkg-1. A solution of 0.45 M NaNO3+1% (v/v) ethylene glycol in 0.3 mL-min-1 is used as an eluent, and the samples should be diluted in the mobile phase. Column and precolumn were maintained at 70.degree. C., detection is performed by refractometry.

[0151] For the NMR analyses, the synthesised polymers were stored at -80.degree. C. overnight and then be freeze-dried (CHRIST ALPHA apparatus 2-4). 10 mg of the powder obtained are then dissolved in 0.5 mL of deuterated water and analysed by proton NMR. The 1H NMR spectra were acquired on a spectrometer BRUKER AVANCE (500 MHz). The data were then treated with the TOPSPIN 3.0 software.

[0152] FIG. 2 shows the HPAEC-PAD profiles of a reaction using dextran 1500 Da as an acceptor.

[0153] FIG. 3 shows the profile NMR of dextran 1500 Da obtained at the end of incubation.

[0154] FIG. 4 shows the HPAEC-PAD profiles of endodextranase digestion of the products of the sucrose+dextran 1500 Da acceptor reaction (to=1500 Da dextran connected in .alpha.-1,3).

[0155] While no polymerisation was observed in the presence of sucrose, the results revealed a characteristic modification of dextran. A more detailed analysis of chromatographic results and structural analyses by proton NMR show the synthesis of branches in .alpha.-1,3 on the acceptor molecule (FIGS. 2 and 3). In particular, the reaction product is resistant to the action of an endodextranase, an enzyme specific for the hydrolysis of .alpha.-1,6 bonds (FIG. 4). More broadly, these results suggest a resistance to the action of digestive enzymes, and therefore the existence of prebiotic properties comparable to those of isomaltooligosaccharides or gluco-oligosaccharides connected in .alpha.-1,2 (GOFFIN et al. Crit Rev. Food Sci. Nutr., vol. 51(5), p:394-409, 2011; SARBINI et al., Appl. Environ. Microbiol., vol. 77(15), p:5307-15, 2011).

[0156] The enzyme, as its truncated form, is particularly effective shown also to catalyse the transfer of glycosyl residues on isomaltooligosaccharides since the addition of dextran 1500 Da as an acceptor molecule in the reaction medium has the effect of multiplying the activity of the enzyme by a factor of 26 (compared to the activity measured on sucrose alone).

[0157] Finally, these results demonstrate that the identified protein is responsible for the connections in .alpha.-1,3 of the glucan corresponding to the proportion S and that a single enzyme, as was previously believed, is not the initiator of the synthesis of this specific glucan. Because of this activity, the corresponding gene encoding an "enzyme responsible for glucosylations specific by connection in .alpha.-1,3" is named .alpha.-1,3BrS.

Example 4

Influence of Changes in Concentration of Substrate/Acceptor on the Number of Connections Obtained in Alpha-1,3

[0158] Additional experiments have also shown that by varying the sucrose concentration relative to the concentration of dextran 1500 Da (donor/acceptor ratio), it is possible to control the degree of connection in .alpha.-1,3 of this the small dextran.

[0159] FIG. 5 shows the control of the rate of .alpha.-1,3 bonds according to the sucrose/dextran 1500 Da ratio (using mass concentrations).

[0160] FIG. 6 also shows the control of the rate of .alpha.-1,3 bonds according to the sucrose/dextran 1500 Da ratio but with the truncated enzyme.

[0161] The results show that at a sucrose/Dextran 1500 ratio (equivalent to a substrate/hydroxyl moiety ratio) greater than or equal to 1, we arrive at a degree of substitution of about 40% and approaches 50% by increasing the substrate concentration. Now, by modulating this report, we come to reduce the substitution rate. Thus, for a 1/2 ratio, the substitution rate is slightly lower than 25%, and a ratio of 1/3, the rate of substitution rises and is slightly below 15%.

[0162] Note that the inventors on the same substrate with the truncated form came to the same results (FIG. 6), confirming that the truncated enzyme retains the same specificity as the whole shape.

Example 5

Dextran Acceptors

[0163] .fwdarw. Moreover, the enzyme and its truncated form have proved capable of carrying out such connection reactions in .alpha.-1,3 over a wide range of higher molecular weight dextrans. Tests were performed out on particular dextran 68.4 kDa, 503 kDa and 2.times.10.sup.6 Da. Based on proton NMR analyses, the high molecular weight dextrans have 50% of .alpha.-1,3 bonds (FIGS. 7 and 8). Here again we find the comb-like structure described in the '80s in the work on the native glucan produced by the strain.

[0164] FIGS. 7 and 8 show the NMR spectrum of dextran 68.4 kDa connected in .alpha.-1,3 obtained with the whole enzyme and the truncated enzyme respectively.

[0165] These results show that the .alpha.-1,3BrS is therefore able to recognise and connect many dextrans having a molecular weight between 1.5 and 2.times.10.sup.6 kDa. We can therefore offer a range of products from small prebiotic gluco-oligosaccharides to high molecular weight polymers, with rates controlled (like) of connections in .alpha.-1,3.

Example 6

Identification of an Orthologue in L. citreum

[0166] With this characterisation, the inventors sought orthologues to this enzyme, which allowed identification of such an orthologue of this enzyme in the genome of the strain L. citreum LBAE E16 (SEQ ID no 14 and SEQ ID no 15 for the nucleic and protein sequences of this orthologue respectively).

[0167] A comparative analysis of the newly identified with the previous sequence has revealed that they share 98% identity for the complete sequence with an identity of 100% with respect to the patterns I to IV of the catalytic heart.

Example 7

Identification of an Ortholog in L. fallax

[0168] The identification of an orthologue opened the way to research on other orthologues in other species, which has allowed the inventors to identify at the strain KCTC 3537 Leuconostoc fallax a protein (SEQ ID no 17) having an overall identity of about 54% with the protein sequence of .alpha.-1,3 BrS, which rises to 68% when we focus on the catalytic domains A, B and C.

[0169] An analysis of the catalytic units I, II, III and IV shows a slight discrepancy regarding the pattern III

TABLE-US-00002 Pattern II Pattern III Pattern IV Pattern I (SEQ ID no) (SEQ ID no) (SEQ ID no) (SEQ ID no) .alpha.-1,3 BrS SMRIDAISFVD HISIVEAPKGE IVHAHDKDIQ ADFVANQ (19) (20) DTVIH (21) (18) GH L.fallax SIRIDAISFVD HVSIVEASADQ IVHAHDKDIQ ADYVANQ (23) (24) DAVSN (25) (22) Identity (%) 90 54,5 80 85

[0170] As above, the inventors conducted a cloning of this putative hydrolase glycoside and its recombinant expression in E. coli.

[0171] To do so, the inventors have previously made a synthetic gene (SEQ ID no 16) by codon optimisation of the wild-type gene, to facilitate recombinant expression of the protein in E. coli BL21 star DE3 as before. The production of the protein allowed to obtain an amount of protein for characterisation (output 2.5 times greater than that obtained for .alpha.-1,3 BrS).

[0172] Brought into contact with sucrose only, the enzyme revealed, as for the .alpha.-1,3 BrS, its inability to polymerise the glucosyl units. Now, as for the .alpha.-1,3 BrS, it showed its ability to make connections in .alpha.-1,3 on a dextran 1500 Da with a connection rate of 37%.

Example 8

Development of a Method in One Single Step for the Production of Oligosaccharides with Connections Controlled in .alpha.-1,3

[0173] This process involves the implementation of a polymerase of the family GH-70 coupled with the action of the enzyme .alpha.-1.3 BrS on sucrose alone.

[0174] In its implementation, the method is tested on a variable proportion of the two enzymes.

[0175] The products formed from the enzymatic reaction are analysed by chromatography (HPAEC-PAD, HPSEC to determine the size of the oligosaccharides produced) and NMR of the proton (determination of the proportion of .alpha.-1,3 bonds).

Example 9

Assessment of Physico-Chemical Properties of Very High Molecular Mass Glucans with Controlled Content of .alpha.-1,3 Bonds

[0176] Different high molecular weight glucans are incubated in the presence of the .alpha.-1,3 BrS enzyme. The physicochemical properties of the resulting glucans are investigated, in particular by thermogravimetric analysis, by determining the glass transition temperature, and rheological analysis (see IRAGUE et al, Biomacromolecules, 2012).

Example 10

Assessment of Physico-Chemical Properties of Very High Molecular Mass Glucans with Controlled Content of .alpha.-1,2 and .alpha.-1.3 Bonds

[0177] Different very high molecular mass glucans are incubated in the presence of the enzyme .alpha.-1,3 BrS and of the enzyme GBD-CD2 (BRISON and al., 2009) which shows a connecting activity in .alpha.-1,2. The physicochemical properties of the resulting glucans are investigated, in particular by thermogravimetric analysis, by determining the glass transition temperature, and rheological analysis (see IRAGUE et al, Biomacromolecules, 2012).

Example 11

Assessment of Physico-Chemical and Prebiotic Properties of Oligosaccharides with a Controlled Content in .alpha.-1,2 and .alpha.-1.3 Bonds

[0178] Isomaltooligosaccharides are incubated in the presence of the enzyme .alpha.-1,3 BrS and of the enzyme GBD-CD2 which shows a connecting activity in .alpha.-1,2. Prebiotics and physicochemical properties of the resulting glucans are investigated.

Example 12

Evaluation of the Prebiotic, Nutritional Properties and of the Metabolic Effects of Oligosaccharides Connected in .alpha.-1.3

[0179] These properties are tested for different oligosaccharides connected with the enzyme .alpha.-1,3 BrS.

Example 13

Screening of a Library Acceptor

[0180] The enzyme .alpha.-1,3 BrS is put in the presence of its natural substrate (sucrose) and a panel of different acceptors, including dextrans connected in .alpha.-1.2 (BRISON et al., 2009), of mutans, of alternans, of reuterans, of fructans and of fructooligosaccharides, of polyphenols, of flavonoids, of amino acids. The reaction products are analysed by various chromatographic techniques (mass spectrometry, HPAEC-PAD) and by NMR.

[0181] These experiments have already shown that this enzyme allows the glycosylation of oligosaccharides such as the fructoologosaccharides (FOS) and xylooligosaccharides (XOS)

Example 14

Screening of a Donor Library

[0182] The enzyme .alpha.-1,3 BrS is implemented on various analogues of sucrose (DAUDE et al, 2012) which can serve as donor of glucosyl units.

Sequence CWU 1

1

2417PRTArtificial Sequenceenzymatic domain 1Ala Asp Xaa Val Ala Asn Gln 1 5 211PRTArtificial Sequenceenzymatic domain 2Ser Xaa Arg Ile Asp Ala Ile Ser Phe Val Asp 1 5 10 311PRTArtificial Sequenceenzymatic domain 3His Xaa Ser Ile Val Glu Ala Xaa Xaa Xaa Xaa 1 5 10 415PRTArtificial Sequenceenzymatic domain 4Ile Val His Ala His Asp Lys Asp Ile Gln Asp Xaa Val Xaa Xaa 1 5 10 15 5635PRTArtificial Sequencestructural domain 5Asn Pro Val Val Gln Ala Glu Gln Leu Asn Trp Leu Tyr Tyr Leu Met 1 5 10 15 Asn Phe Gly Gln Ile Thr Ala Asn Asp Ser Asn Ala Asn Phe Asp Ser 20 25 30 Met Arg Ile Asp Ala Ile Ser Phe Val Asp Pro Gln Ile Ala Lys Lys 35 40 45 Ala Tyr Asp Leu Leu Asp Lys Met Tyr Gly Leu Thr Asp Asn Glu Ala 50 55 60 Val Ala Asn Gln His Ile Ser Ile Val Glu Ala Pro Lys Gly Glu Thr 65 70 75 80 Pro Ile Thr Val Glu Lys Gln Ser Ala Leu Val Glu Ser Asn Trp Arg 85 90 95 Asp Arg Met Lys Gln Ser Leu Ser Lys Asn Ala Thr Leu Asp Lys Leu 100 105 110 Asp Pro Asp Pro Ala Ile Asn Ser Leu Glu Lys Leu Val Ala Asp Asp 115 120 125 Leu Val Asn Arg Ser Gln Ser Ser Asp Lys Asp Ser Ser Thr Ile Pro 130 135 140 Asn Tyr Ser Ile Val His Ala His Asp Lys Asp Ile Gln Asp Thr Val 145 150 155 160 Ile His Ile Met Lys Ile Val Asn Asn Asn Pro Asn Ile Ser Met Ser 165 170 175 Asp Phe Thr Met Gln Gln Leu Gln Asn Gly Leu Lys Ala Phe Tyr Glu 180 185 190 Asp Gln His Gln Ser Val Lys Lys Tyr Asn Gln Tyr Asn Ile Pro Ser 195 200 205 Ala Tyr Ala Leu Leu Leu Thr Asn Lys Asp Thr Val Pro Arg Val Phe 210 215 220 Tyr Gly Asp Met Tyr Gln Asp Tyr Gly Asp Asp Leu Asp Gly Gly Gln 225 230 235 240 Tyr Met Ala Thr Lys Ser Ile Tyr Tyr Asn Ala Ile Glu Gln Met Met 245 250 255 Lys Ala Arg Leu Lys Tyr Val Ala Gly Gly Gln Ile Met Ala Val Thr 260 265 270 Lys Ile Lys Asn Asp Gly Ile Asn Lys Asp Gly Thr Asn Lys Ser Gly 275 280 285 Glu Val Leu Thr Ser Val Arg Phe Gly Lys Asp Ile Met Asp Ala Gln 290 295 300 Gly Gln Gly Thr Ala Glu Ser Arg Asn Gln Gly Ile Gly Val Ile Val 305 310 315 320 Ser Asn Ser Ser Gly Leu Glu Leu Lys Asn Ser Asp Ser Ile Thr Leu 325 330 335 His Met Gly Ile Ala His Lys Asn Gln Ala Tyr Arg Ala Leu Met Leu 340 345 350 Thr Asn Asp Lys Gly Ile Val Asn Tyr Asp Gln Asp Asn Asn Ala Pro 355 360 365 Ile Ala Trp Thr Asn Asp His Gly Asp Leu Ile Phe Thr Asn Gln Met 370 375 380 Ile Asn Gly Gln Ser Asp Thr Ala Val Lys Gly Tyr Leu Asn Pro Glu 385 390 395 400 Val Ala Gly Tyr Leu Ala Val Trp Val Pro Val Gly Ala Asn Asp Asn 405 410 415 Gln Asp Ala Arg Thr Val Thr Thr Asn Gln Lys Asn Thr Asp Gly Lys 420 425 430 Val Leu His Thr Asn Ala Ala Leu Asp Ser Lys Leu Met Tyr Glu Gly 435 440 445 Phe Ser Asn Phe Gln Lys Met Pro Thr Arg Gly Asn Gln Tyr Ala Asn 450 455 460 Val Val Ile Thr Lys Asn Ile Asp Leu Phe Lys Ser Trp Gly Ile Thr 465 470 475 480 Asp Phe Glu Leu Ala Pro Gln Tyr Arg Ser Ser Asp Gly Lys Asp Ile 485 490 495 Thr Asp Arg Phe Leu Asp Ser Ile Val Gln Asn Gly Tyr Gly Leu Ser 500 505 510 Asp Arg Tyr Asp Leu Gly Phe Lys Thr Pro Thr Lys Tyr Gly Thr Asp 515 520 525 Gln Asp Leu Arg Lys Ala Ile Glu Arg Leu His Gln Ala Gly Met Ser 530 535 540 Val Met Ala Asp Phe Val Ala Asn Gln Ile Tyr Gly Leu His Ala Asp 545 550 555 560 Lys Glu Val Val Ser Ala Gln His Val Asn Ile Asn Gly Asp Thr Lys 565 570 575 Leu Val Val Asp Pro Arg Tyr Gly Thr Gln Met Thr Val Val Asn Ser 580 585 590 Val Gly Gly Gly Asp Tyr Gln Ala Lys Tyr Gly Gly Glu Tyr Leu Asp 595 600 605 Thr Ile Ser Lys Leu Tyr Pro Gly Leu Leu Leu Asp Ser Asn Gly Gln 610 615 620 Lys Ile Asp Leu Ser Thr Lys Ile Lys Glu Trp 625 630 635 6699PRTArtificial Sequencestructural domain 6Asn Val Asp Ser Glu Tyr Pro Gly Gly Trp Phe Gln Gly Gly Tyr Leu 1 5 10 15 Ala Tyr Gln Asn Ser Asp Leu Thr Pro Tyr Ala Asn Thr Asn Pro Asp 20 25 30 Tyr Arg Thr His Asn Gly Leu Glu Phe Leu Leu Ala Asn Asp Val Asp 35 40 45 Asn Ser Asn Pro Val Val Gln Ala Glu Gln Leu Asn Trp Leu Tyr Tyr 50 55 60 Leu Met Asn Phe Gly Gln Ile Thr Ala Asn Asp Ser Asn Ala Asn Phe 65 70 75 80 Asp Ser Met Arg Ile Asp Ala Ile Ser Phe Val Asp Pro Gln Ile Ala 85 90 95 Lys Lys Ala Tyr Asp Leu Leu Asp Lys Met Tyr Gly Leu Thr Asp Asn 100 105 110 Glu Ala Val Ala Asn Gln His Ile Ser Ile Val Glu Ala Pro Lys Gly 115 120 125 Glu Thr Pro Ile Thr Val Glu Lys Gln Ser Ala Leu Val Glu Ser Asn 130 135 140 Trp Arg Asp Arg Met Lys Gln Ser Leu Ser Lys Asn Ala Thr Leu Asp 145 150 155 160 Lys Leu Asp Pro Asp Pro Ala Ile Asn Ser Leu Glu Lys Leu Val Ala 165 170 175 Asp Asp Leu Val Asn Arg Ser Gln Ser Ser Asp Lys Asp Ser Ser Thr 180 185 190 Ile Pro Asn Tyr Ser Ile Val His Ala His Asp Lys Asp Ile Gln Asp 195 200 205 Thr Val Ile His Ile Met Lys Ile Val Asn Asn Asn Pro Asn Ile Ser 210 215 220 Met Ser Asp Phe Thr Met Gln Gln Leu Gln Asn Gly Leu Lys Ala Phe 225 230 235 240 Tyr Glu Asp Gln His Gln Ser Val Lys Lys Tyr Asn Gln Tyr Asn Ile 245 250 255 Pro Ser Ala Tyr Ala Leu Leu Leu Thr Asn Lys Asp Thr Val Pro Arg 260 265 270 Val Phe Tyr Gly Asp Met Tyr Gln Asp Tyr Gly Asp Asp Leu Asp Gly 275 280 285 Gly Gln Tyr Met Ala Thr Lys Ser Ile Tyr Tyr Asn Ala Ile Glu Gln 290 295 300 Met Met Lys Ala Arg Leu Lys Tyr Val Ala Gly Gly Gln Ile Met Ala 305 310 315 320 Val Thr Lys Ile Lys Asn Asp Gly Ile Asn Lys Asp Gly Thr Asn Lys 325 330 335 Ser Gly Glu Val Leu Thr Ser Val Arg Phe Gly Lys Asp Ile Met Asp 340 345 350 Ala Gln Gly Gln Gly Thr Ala Glu Ser Arg Asn Gln Gly Ile Gly Val 355 360 365 Ile Val Ser Asn Ser Ser Gly Leu Glu Leu Lys Asn Ser Asp Ser Ile 370 375 380 Thr Leu His Met Gly Ile Ala His Lys Asn Gln Ala Tyr Arg Ala Leu 385 390 395 400 Met Leu Thr Asn Asp Lys Gly Ile Val Asn Tyr Asp Gln Asp Asn Asn 405 410 415 Ala Pro Ile Ala Trp Thr Asn Asp His Gly Asp Leu Ile Phe Thr Asn 420 425 430 Gln Met Ile Asn Gly Gln Ser Asp Thr Ala Val Lys Gly Tyr Leu Asn 435 440 445 Pro Glu Val Ala Gly Tyr Leu Ala Val Trp Val Pro Val Gly Ala Asn 450 455 460 Asp Asn Gln Asp Ala Arg Thr Val Thr Thr Asn Gln Lys Asn Thr Asp 465 470 475 480 Gly Lys Val Leu His Thr Asn Ala Ala Leu Asp Ser Lys Leu Met Tyr 485 490 495 Glu Gly Phe Ser Asn Phe Gln Lys Met Pro Thr Arg Gly Asn Gln Tyr 500 505 510 Ala Asn Val Val Ile Thr Lys Asn Ile Asp Leu Phe Lys Ser Trp Gly 515 520 525 Ile Thr Asp Phe Glu Leu Ala Pro Gln Tyr Arg Ser Ser Asp Gly Lys 530 535 540 Asp Ile Thr Asp Arg Phe Leu Asp Ser Ile Val Gln Asn Gly Tyr Gly 545 550 555 560 Leu Ser Asp Arg Tyr Asp Leu Gly Phe Lys Thr Pro Thr Lys Tyr Gly 565 570 575 Thr Asp Gln Asp Leu Arg Lys Ala Ile Glu Arg Leu His Gln Ala Gly 580 585 590 Met Ser Val Met Ala Asp Phe Val Ala Asn Gln Ile Tyr Gly Leu His 595 600 605 Ala Asp Lys Glu Val Val Ser Ala Gln His Val Asn Ile Asn Gly Asp 610 615 620 Thr Lys Leu Val Val Asp Pro Arg Tyr Gly Thr Gln Met Thr Val Val 625 630 635 640 Asn Ser Val Gly Gly Gly Asp Tyr Gln Ala Lys Tyr Gly Gly Glu Tyr 645 650 655 Leu Asp Thr Ile Ser Lys Leu Tyr Pro Gly Leu Leu Leu Asp Ser Asn 660 665 670 Gly Gln Lys Ile Asp Leu Ser Thr Lys Ile Lys Glu Trp Ser Ala Lys 675 680 685 Tyr Leu Asn Gly Ser Asn Ile Pro Gln Val Gly 690 695 7911PRTArtificial Sequencestructural domain 7Val Lys Asp Val Tyr Ser Gln His Asn Ala Val Asn Asn Leu Ser Ala 1 5 10 15 Asn Asn Phe Lys Asn Leu Val Asp Gly Phe Leu Thr Ala Glu Thr Trp 20 25 30 Tyr Arg Pro Ala Gln Ile Leu Ser His Gly Thr Asp Trp Val Ala Ser 35 40 45 Thr Asp Lys Asp Phe Arg Pro Leu Ile Thr Val Trp Trp Pro Asn Lys 50 55 60 Asp Ile Gln Val Asn Tyr Leu Lys Leu Met Gln Gln Ile Gly Ile Leu 65 70 75 80 Asp Asn Ser Val Val Phe Asp Thr Asn Asn Asp Gln Leu Val Leu Asn 85 90 95 Lys Gly Ala Glu Ser Ala Gln Ile Gly Ile Glu Lys Lys Val Ser Glu 100 105 110 Thr Gly Asn Thr Asp Trp Leu Asn Glu Leu Leu Phe Ala Pro Asn Gly 115 120 125 Asn Gln Pro Ser Phe Ile Lys Gln Gln Tyr Leu Trp Asn Val Asp Ser 130 135 140 Glu Tyr Pro Gly Gly Trp Phe Gln Gly Gly Tyr Leu Ala Tyr Gln Asn 145 150 155 160 Ser Asp Leu Thr Pro Tyr Ala Asn Thr Asn Pro Asp Tyr Arg Thr His 165 170 175 Asn Gly Leu Glu Phe Leu Leu Ala Asn Asp Val Asp Asn Ser Asn Pro 180 185 190 Val Val Gln Ala Glu Gln Leu Asn Trp Leu Tyr Tyr Leu Met Asn Phe 195 200 205 Gly Gln Ile Thr Ala Asn Asp Ser Asn Ala Asn Phe Asp Ser Met Arg 210 215 220 Ile Asp Ala Ile Ser Phe Val Asp Pro Gln Ile Ala Lys Lys Ala Tyr 225 230 235 240 Asp Leu Leu Asp Lys Met Tyr Gly Leu Thr Asp Asn Glu Ala Val Ala 245 250 255 Asn Gln His Ile Ser Ile Val Glu Ala Pro Lys Gly Glu Thr Pro Ile 260 265 270 Thr Val Glu Lys Gln Ser Ala Leu Val Glu Ser Asn Trp Arg Asp Arg 275 280 285 Met Lys Gln Ser Leu Ser Lys Asn Ala Thr Leu Asp Lys Leu Asp Pro 290 295 300 Asp Pro Ala Ile Asn Ser Leu Glu Lys Leu Val Ala Asp Asp Leu Val 305 310 315 320 Asn Arg Ser Gln Ser Ser Asp Lys Asp Ser Ser Thr Ile Pro Asn Tyr 325 330 335 Ser Ile Val His Ala His Asp Lys Asp Ile Gln Asp Thr Val Ile His 340 345 350 Ile Met Lys Ile Val Asn Asn Asn Pro Asn Ile Ser Met Ser Asp Phe 355 360 365 Thr Met Gln Gln Leu Gln Asn Gly Leu Lys Ala Phe Tyr Glu Asp Gln 370 375 380 His Gln Ser Val Lys Lys Tyr Asn Gln Tyr Asn Ile Pro Ser Ala Tyr 385 390 395 400 Ala Leu Leu Leu Thr Asn Lys Asp Thr Val Pro Arg Val Phe Tyr Gly 405 410 415 Asp Met Tyr Gln Asp Tyr Gly Asp Asp Leu Asp Gly Gly Gln Tyr Met 420 425 430 Ala Thr Lys Ser Ile Tyr Tyr Asn Ala Ile Glu Gln Met Met Lys Ala 435 440 445 Arg Leu Lys Tyr Val Ala Gly Gly Gln Ile Met Ala Val Thr Lys Ile 450 455 460 Lys Asn Asp Gly Ile Asn Lys Asp Gly Thr Asn Lys Ser Gly Glu Val 465 470 475 480 Leu Thr Ser Val Arg Phe Gly Lys Asp Ile Met Asp Ala Gln Gly Gln 485 490 495 Gly Thr Ala Glu Ser Arg Asn Gln Gly Ile Gly Val Ile Val Ser Asn 500 505 510 Ser Ser Gly Leu Glu Leu Lys Asn Ser Asp Ser Ile Thr Leu His Met 515 520 525 Gly Ile Ala His Lys Asn Gln Ala Tyr Arg Ala Leu Met Leu Thr Asn 530 535 540 Asp Lys Gly Ile Val Asn Tyr Asp Gln Asp Asn Asn Ala Pro Ile Ala 545 550 555 560 Trp Thr Asn Asp His Gly Asp Leu Ile Phe Thr Asn Gln Met Ile Asn 565 570 575 Gly Gln Ser Asp Thr Ala Val Lys Gly Tyr Leu Asn Pro Glu Val Ala 580 585 590 Gly Tyr Leu Ala Val Trp Val Pro Val Gly Ala Asn Asp Asn Gln Asp 595 600 605 Ala Arg Thr Val Thr Thr Asn Gln Lys Asn Thr Asp Gly Lys Val Leu 610 615 620 His Thr Asn Ala Ala Leu Asp Ser Lys Leu Met Tyr Glu Gly Phe Ser 625 630 635 640 Asn Phe Gln Lys Met Pro Thr Arg Gly Asn Gln Tyr Ala Asn Val Val 645 650 655 Ile Thr Lys Asn Ile Asp Leu Phe Lys Ser Trp Gly Ile Thr Asp Phe 660 665 670 Glu Leu Ala Pro Gln Tyr Arg Ser Ser Asp Gly Lys Asp Ile Thr Asp 675 680 685 Arg Phe Leu Asp Ser Ile Val Gln Asn Gly Tyr Gly Leu Ser Asp Arg 690 695 700 Tyr Asp Leu Gly Phe Lys Thr Pro Thr Lys Tyr Gly Thr Asp Gln Asp 705 710 715 720 Leu Arg Lys Ala Ile Glu Arg Leu His Gln Ala Gly Met Ser Val Met 725 730 735 Ala Asp Phe Val Ala Asn Gln Ile Tyr Gly Leu His Ala Asp Lys Glu 740 745 750 Val Val Ser Ala Gln His Val Asn Ile Asn Gly Asp Thr Lys Leu Val 755 760 765 Val Asp Pro Arg Tyr Gly Thr Gln Met Thr Val Val Asn Ser Val Gly 770 775 780 Gly Gly Asp Tyr Gln Ala Lys Tyr Gly Gly Glu Tyr Leu Asp Thr Ile 785 790 795 800 Ser Lys Leu Tyr Pro Gly Leu Leu Leu Asp Ser Asn Gly Gln Lys Ile 805 810 815 Asp Leu Ser Thr Lys Ile Lys Glu Trp Ser Ala Lys Tyr Leu Asn Gly 820 825 830 Ser Asn Ile Pro Gln Val Gly Met Gly Tyr Val Leu Lys Asp Trp Asn 835 840 845 Asn Gly Gln Tyr Phe His Ile Leu Asp Lys Glu Gly Gln Tyr Ser Leu 850 855 860 Pro Thr Gln Leu Val Ser Asn Asp Pro Glu Thr Gln Ile Gly Glu Ser 865 870 875 880 Val Asn Tyr Lys Tyr Phe Ile Gly Asn Ser Asp Ala Thr Tyr Asn Met

885 890 895 Tyr His Asn Leu Pro Asn Thr Val Ser Leu Ile Asn Ser Gln Glu 900 905 910 81204PRTArtificial Sequencestructural domain 8Leu Asn Tyr Phe Asp Leu Ala Thr Gly Ile Gln Leu Lys Gly Gln Ala 1 5 10 15 Lys Asn Ile Asp Gly Ile Gly Tyr Tyr Phe Asp Gln Asn Asn Gly Asn 20 25 30 Gly Glu Tyr Arg Tyr Ser Leu Thr Gly Pro Val Val Lys Asp Val Tyr 35 40 45 Ser Gln His Asn Ala Val Asn Asn Leu Ser Ala Asn Asn Phe Lys Asn 50 55 60 Leu Val Asp Gly Phe Leu Thr Ala Glu Thr Trp Tyr Arg Pro Ala Gln 65 70 75 80 Ile Leu Ser His Gly Thr Asp Trp Val Ala Ser Thr Asp Lys Asp Phe 85 90 95 Arg Pro Leu Ile Thr Val Trp Trp Pro Asn Lys Asp Ile Gln Val Asn 100 105 110 Tyr Leu Lys Leu Met Gln Gln Ile Gly Ile Leu Asp Asn Ser Val Val 115 120 125 Phe Asp Thr Asn Asn Asp Gln Leu Val Leu Asn Lys Gly Ala Glu Ser 130 135 140 Ala Gln Ile Gly Ile Glu Lys Lys Val Ser Glu Thr Gly Asn Thr Asp 145 150 155 160 Trp Leu Asn Glu Leu Leu Phe Ala Pro Asn Gly Asn Gln Pro Ser Phe 165 170 175 Ile Lys Gln Gln Tyr Leu Trp Asn Val Asp Ser Glu Tyr Pro Gly Gly 180 185 190 Trp Phe Gln Gly Gly Tyr Leu Ala Tyr Gln Asn Ser Asp Leu Thr Pro 195 200 205 Tyr Ala Asn Thr Asn Pro Asp Tyr Arg Thr His Asn Gly Leu Glu Phe 210 215 220 Leu Leu Ala Asn Asp Val Asp Asn Ser Asn Pro Val Val Gln Ala Glu 225 230 235 240 Gln Leu Asn Trp Leu Tyr Tyr Leu Met Asn Phe Gly Gln Ile Thr Ala 245 250 255 Asn Asp Ser Asn Ala Asn Phe Asp Ser Met Arg Ile Asp Ala Ile Ser 260 265 270 Phe Val Asp Pro Gln Ile Ala Lys Lys Ala Tyr Asp Leu Leu Asp Lys 275 280 285 Met Tyr Gly Leu Thr Asp Asn Glu Ala Val Ala Asn Gln His Ile Ser 290 295 300 Ile Val Glu Ala Pro Lys Gly Glu Thr Pro Ile Thr Val Glu Lys Gln 305 310 315 320 Ser Ala Leu Val Glu Ser Asn Trp Arg Asp Arg Met Lys Gln Ser Leu 325 330 335 Ser Lys Asn Ala Thr Leu Asp Lys Leu Asp Pro Asp Pro Ala Ile Asn 340 345 350 Ser Leu Glu Lys Leu Val Ala Asp Asp Leu Val Asn Arg Ser Gln Ser 355 360 365 Ser Asp Lys Asp Ser Ser Thr Ile Pro Asn Tyr Ser Ile Val His Ala 370 375 380 His Asp Lys Asp Ile Gln Asp Thr Val Ile His Ile Met Lys Ile Val 385 390 395 400 Asn Asn Asn Pro Asn Ile Ser Met Ser Asp Phe Thr Met Gln Gln Leu 405 410 415 Gln Asn Gly Leu Lys Ala Phe Tyr Glu Asp Gln His Gln Ser Val Lys 420 425 430 Lys Tyr Asn Gln Tyr Asn Ile Pro Ser Ala Tyr Ala Leu Leu Leu Thr 435 440 445 Asn Lys Asp Thr Val Pro Arg Val Phe Tyr Gly Asp Met Tyr Gln Asp 450 455 460 Tyr Gly Asp Asp Leu Asp Gly Gly Gln Tyr Met Ala Thr Lys Ser Ile 465 470 475 480 Tyr Tyr Asn Ala Ile Glu Gln Met Met Lys Ala Arg Leu Lys Tyr Val 485 490 495 Ala Gly Gly Gln Ile Met Ala Val Thr Lys Ile Lys Asn Asp Gly Ile 500 505 510 Asn Lys Asp Gly Thr Asn Lys Ser Gly Glu Val Leu Thr Ser Val Arg 515 520 525 Phe Gly Lys Asp Ile Met Asp Ala Gln Gly Gln Gly Thr Ala Glu Ser 530 535 540 Arg Asn Gln Gly Ile Gly Val Ile Val Ser Asn Ser Ser Gly Leu Glu 545 550 555 560 Leu Lys Asn Ser Asp Ser Ile Thr Leu His Met Gly Ile Ala His Lys 565 570 575 Asn Gln Ala Tyr Arg Ala Leu Met Leu Thr Asn Asp Lys Gly Ile Val 580 585 590 Asn Tyr Asp Gln Asp Asn Asn Ala Pro Ile Ala Trp Thr Asn Asp His 595 600 605 Gly Asp Leu Ile Phe Thr Asn Gln Met Ile Asn Gly Gln Ser Asp Thr 610 615 620 Ala Val Lys Gly Tyr Leu Asn Pro Glu Val Ala Gly Tyr Leu Ala Val 625 630 635 640 Trp Val Pro Val Gly Ala Asn Asp Asn Gln Asp Ala Arg Thr Val Thr 645 650 655 Thr Asn Gln Lys Asn Thr Asp Gly Lys Val Leu His Thr Asn Ala Ala 660 665 670 Leu Asp Ser Lys Leu Met Tyr Glu Gly Phe Ser Asn Phe Gln Lys Met 675 680 685 Pro Thr Arg Gly Asn Gln Tyr Ala Asn Val Val Ile Thr Lys Asn Ile 690 695 700 Asp Leu Phe Lys Ser Trp Gly Ile Thr Asp Phe Glu Leu Ala Pro Gln 705 710 715 720 Tyr Arg Ser Ser Asp Gly Lys Asp Ile Thr Asp Arg Phe Leu Asp Ser 725 730 735 Ile Val Gln Asn Gly Tyr Gly Leu Ser Asp Arg Tyr Asp Leu Gly Phe 740 745 750 Lys Thr Pro Thr Lys Tyr Gly Thr Asp Gln Asp Leu Arg Lys Ala Ile 755 760 765 Glu Arg Leu His Gln Ala Gly Met Ser Val Met Ala Asp Phe Val Ala 770 775 780 Asn Gln Ile Tyr Gly Leu His Ala Asp Lys Glu Val Val Ser Ala Gln 785 790 795 800 His Val Asn Ile Asn Gly Asp Thr Lys Leu Val Val Asp Pro Arg Tyr 805 810 815 Gly Thr Gln Met Thr Val Val Asn Ser Val Gly Gly Gly Asp Tyr Gln 820 825 830 Ala Lys Tyr Gly Gly Glu Tyr Leu Asp Thr Ile Ser Lys Leu Tyr Pro 835 840 845 Gly Leu Leu Leu Asp Ser Asn Gly Gln Lys Ile Asp Leu Ser Thr Lys 850 855 860 Ile Lys Glu Trp Ser Ala Lys Tyr Leu Asn Gly Ser Asn Ile Pro Gln 865 870 875 880 Val Gly Met Gly Tyr Val Leu Lys Asp Trp Asn Asn Gly Gln Tyr Phe 885 890 895 His Ile Leu Asp Lys Glu Gly Gln Tyr Ser Leu Pro Thr Gln Leu Val 900 905 910 Ser Asn Asp Pro Glu Thr Gln Ile Gly Glu Ser Val Asn Tyr Lys Tyr 915 920 925 Phe Ile Gly Asn Ser Asp Ala Thr Tyr Asn Met Tyr His Asn Leu Pro 930 935 940 Asn Thr Val Ser Leu Ile Asn Ser Gln Glu Gly Gln Ile Lys Thr Gln 945 950 955 960 Gln Ser Gly Val Thr Ser Asp Tyr Glu Gly Gln Gln Val Gln Val Thr 965 970 975 Arg Gln Tyr Thr Asp Ser Lys Gly Val Ser Trp Asn Leu Ile Thr Phe 980 985 990 Ala Gly Gly Asp Leu Gln Gly Gln Lys Leu Trp Val Asp Ser Arg Ala 995 1000 1005 Leu Thr Met Thr Pro Phe Lys Thr Met Asn Gln Ile Ser Phe Ile 1010 1015 1020 Ser Tyr Ala Asn Arg Asn Asp Gly Leu Phe Leu Asn Ala Pro Tyr 1025 1030 1035 Gln Val Lys Gly Tyr Gln Leu Ala Gly Met Ser Asn Gln Tyr Lys 1040 1045 1050 Gly Gln Gln Val Thr Ile Ala Gly Val Ala Asn Val Ser Gly Lys 1055 1060 1065 Asp Trp Ser Leu Ile Ser Phe Asn Gly Thr Gln Tyr Trp Ile Asp 1070 1075 1080 Ser Gln Ala Leu Asn Thr Asn Phe Thr His Asp Met Asn Gln Lys 1085 1090 1095 Val Phe Val Asn Thr Thr Ser Asn Leu Asp Gly Leu Phe Leu Asn 1100 1105 1110 Ala Pro Tyr Arg Gln Pro Gly Tyr Lys Leu Ala Gly Leu Ala Lys 1115 1120 1125 Asn Tyr Asn Asn Gln Thr Val Thr Val Ser Gln Gln Tyr Phe Asp 1130 1135 1140 Asp Gln Gly Thr Val Trp Ser Glu Val Val Leu Gly Gly Gln Thr 1145 1150 1155 Val Trp Val Asp Asn His Ala Leu Ala Gln Met Gln Val Ser Asp 1160 1165 1170 Thr Ser Gln Gln Leu Tyr Val Asn Ser Asn Gly Arg Asn Asp Gly 1175 1180 1185 Leu Phe Leu Asn Ala Pro Tyr Arg Gly Gln Gly Ser Gln Leu Ile 1190 1195 1200 Gly 91888PRTLeuconostoc citreum 9Met Glu Met Lys Glu Thr Ile Thr Arg Lys Lys Leu Tyr Lys Ser Gly 1 5 10 15 Lys Ser Trp Val Ala Ala Ala Thr Ala Phe Ala Val Met Gly Val Ser 20 25 30 Ala Val Thr Thr Val Ser Ala Asp Thr Gln Thr Pro Val Gly Thr Thr 35 40 45 Gln Ser Gln Gln Asp Leu Thr Gly Gln Thr Gly Gln Asp Lys Pro Thr 50 55 60 Thr Lys Glu Val Ile Asp Lys Lys Glu Pro Val Pro Gln Val Ser Ala 65 70 75 80 Gln Asn Val Gly Asp Leu Ser Ala Asp Ala Lys Thr Pro Lys Ala Asp 85 90 95 Asp Lys Gln Asp Thr Gln Pro Thr Asn Ala Gln Leu Pro Asp Gln Gly 100 105 110 Asn Lys Gln Thr Asn Ser Asn Ser Asp Lys Gly Val Lys Glu Ser Thr 115 120 125 Thr Ala Pro Val Lys Thr Thr Asp Val Pro Ser Lys Ser Val Ala Pro 130 135 140 Glu Thr Asn Thr Ser Ile Asn Gly Gly Gln Tyr Val Glu Lys Asp Gly 145 150 155 160 Gln Phe Val Tyr Ile Asp Gln Ser Gly Lys Gln Val Ser Gly Leu Gln 165 170 175 Asn Ile Glu Gly His Thr Gln Tyr Phe Asp Pro Lys Thr Gly Tyr Gln 180 185 190 Thr Lys Gly Glu Leu Lys Asn Ile Asp Asp Asn Ala Tyr Tyr Phe Asp 195 200 205 Lys Asn Ser Gly Asn Gly Arg Thr Phe Thr Lys Ile Ser Asn Gly Ser 210 215 220 Tyr Ser Glu Lys Asp Gly Met Trp Gln Tyr Val Asp Ser His Asp Lys 225 230 235 240 Gln Pro Val Lys Gly Leu Tyr Asp Val Glu Gly Asn Leu Gln Tyr Phe 245 250 255 Asp Leu Ser Thr Gly Asn Gln Ala Lys His Gln Ile Arg Ser Val Asp 260 265 270 Gly Val Thr Tyr Tyr Phe Asp Ala Asp Ser Gly Asn Ala Thr Ala Phe 275 280 285 Lys Ala Val Thr Asn Gly Arg Tyr Ala Glu Gln Thr Thr Lys Asp Lys 290 295 300 Asp Gly Asn Glu Thr Ser Tyr Trp Ala Tyr Leu Asp Asn Gln Gly Asn 305 310 315 320 Ala Ile Lys Gly Leu Asn Asp Val Asn Gly Glu Ile Gln Tyr Phe Asp 325 330 335 Glu His Thr Gly Glu Gln Leu Lys Gly His Thr Ala Thr Val Asp Gly 340 345 350 Thr Thr Tyr Tyr Phe Glu Gly Asn Lys Gly Asn Leu Val Ser Val Val 355 360 365 Asn Thr Ala Pro Thr Gly Gln Tyr Lys Ile Asn Gly Asp Asn Val Tyr 370 375 380 Tyr Leu Asp Asn Asn Asn Glu Ala Ile Lys Gly Leu Tyr Gly Ile Asn 385 390 395 400 Gly Asn Leu Asn Tyr Phe Asp Leu Ala Thr Gly Ile Gln Leu Lys Gly 405 410 415 Gln Ala Lys Asn Ile Asp Gly Ile Gly Tyr Tyr Phe Asp Gln Asn Asn 420 425 430 Gly Asn Gly Glu Tyr Arg Tyr Ser Leu Thr Gly Pro Val Val Lys Asp 435 440 445 Val Tyr Ser Gln His Asn Ala Val Asn Asn Leu Ser Ala Asn Asn Phe 450 455 460 Lys Asn Leu Val Asp Gly Phe Leu Thr Ala Glu Thr Trp Tyr Arg Pro 465 470 475 480 Ala Gln Ile Leu Ser His Gly Thr Asp Trp Val Ala Ser Thr Asp Lys 485 490 495 Asp Phe Arg Pro Leu Ile Thr Val Trp Trp Pro Asn Lys Asp Ile Gln 500 505 510 Val Asn Tyr Leu Lys Leu Met Gln Gln Ile Gly Ile Leu Asp Asn Ser 515 520 525 Val Val Phe Asp Thr Asn Asn Asp Gln Leu Val Leu Asn Lys Gly Ala 530 535 540 Glu Ser Ala Gln Ile Gly Ile Glu Lys Lys Val Ser Glu Thr Gly Asn 545 550 555 560 Thr Asp Trp Leu Asn Glu Leu Leu Phe Ala Pro Asn Gly Asn Gln Pro 565 570 575 Ser Phe Ile Lys Gln Gln Tyr Leu Trp Asn Val Asp Ser Glu Tyr Pro 580 585 590 Gly Gly Trp Phe Gln Gly Gly Tyr Leu Ala Tyr Gln Asn Ser Asp Leu 595 600 605 Thr Pro Tyr Ala Asn Thr Asn Pro Asp Tyr Arg Thr His Asn Gly Leu 610 615 620 Glu Phe Leu Leu Ala Asn Asp Val Asp Asn Ser Asn Pro Val Val Gln 625 630 635 640 Ala Glu Gln Leu Asn Trp Leu Tyr Tyr Leu Met Asn Phe Gly Gln Ile 645 650 655 Thr Ala Asn Asp Ser Asn Ala Asn Phe Asp Ser Met Arg Ile Asp Ala 660 665 670 Ile Ser Phe Val Asp Pro Gln Ile Ala Lys Lys Ala Tyr Asp Leu Leu 675 680 685 Asp Lys Met Tyr Gly Leu Thr Asp Asn Glu Ala Val Ala Asn Gln His 690 695 700 Ile Ser Ile Val Glu Ala Pro Lys Gly Glu Thr Pro Ile Thr Val Glu 705 710 715 720 Lys Gln Ser Ala Leu Val Glu Ser Asn Trp Arg Asp Arg Met Lys Gln 725 730 735 Ser Leu Ser Lys Asn Ala Thr Leu Asp Lys Leu Asp Pro Asp Pro Ala 740 745 750 Ile Asn Ser Leu Glu Lys Leu Val Ala Asp Asp Leu Val Asn Arg Ser 755 760 765 Gln Ser Ser Asp Lys Asp Ser Ser Thr Ile Pro Asn Tyr Ser Ile Val 770 775 780 His Ala His Asp Lys Asp Ile Gln Asp Thr Val Ile His Ile Met Lys 785 790 795 800 Ile Val Asn Asn Asn Pro Asn Ile Ser Met Ser Asp Phe Thr Met Gln 805 810 815 Gln Leu Gln Asn Gly Leu Lys Ala Phe Tyr Glu Asp Gln His Gln Ser 820 825 830 Val Lys Lys Tyr Asn Gln Tyr Asn Ile Pro Ser Ala Tyr Ala Leu Leu 835 840 845 Leu Thr Asn Lys Asp Thr Val Pro Arg Val Phe Tyr Gly Asp Met Tyr 850 855 860 Gln Asp Tyr Gly Asp Asp Leu Asp Gly Gly Gln Tyr Met Ala Thr Lys 865 870 875 880 Ser Ile Tyr Tyr Asn Ala Ile Glu Gln Met Met Lys Ala Arg Leu Lys 885 890 895 Tyr Val Ala Gly Gly Gln Ile Met Ala Val Thr Lys Ile Lys Asn Asp 900 905 910 Gly Ile Asn Lys Asp Gly Thr Asn Lys Ser Gly Glu Val Leu Thr Ser 915 920 925 Val Arg Phe Gly Lys Asp Ile Met Asp Ala Gln Gly Gln Gly Thr Ala 930 935 940 Glu Ser Arg Asn Gln Gly Ile Gly Val Ile Val Ser Asn Ser Ser Gly 945 950 955 960 Leu Glu Leu Lys Asn Ser Asp Ser Ile Thr Leu His Met Gly Ile Ala 965 970 975 His Lys Asn Gln Ala Tyr Arg Ala Leu Met Leu Thr Asn Asp Lys Gly 980 985 990 Ile Val Asn Tyr Asp Gln Asp Asn Asn Ala Pro Ile Ala Trp Thr Asn 995 1000 1005 Asp His Gly Asp Leu Ile Phe Thr Asn Gln Met Ile Asn Gly Gln 1010 1015 1020 Ser Asp Thr Ala Val Lys Gly Tyr Leu Asn Pro Glu Val Ala Gly 1025 1030 1035 Tyr Leu Ala Val Trp Val Pro Val Gly Ala Asn Asp Asn Gln Asp 1040 1045 1050 Ala Arg Thr Val Thr Thr Asn Gln

Lys Asn Thr Asp Gly Lys Val 1055 1060 1065 Leu His Thr Asn Ala Ala Leu Asp Ser Lys Leu Met Tyr Glu Gly 1070 1075 1080 Phe Ser Asn Phe Gln Lys Met Pro Thr Arg Gly Asn Gln Tyr Ala 1085 1090 1095 Asn Val Val Ile Thr Lys Asn Ile Asp Leu Phe Lys Ser Trp Gly 1100 1105 1110 Ile Thr Asp Phe Glu Leu Ala Pro Gln Tyr Arg Ser Ser Asp Gly 1115 1120 1125 Lys Asp Ile Thr Asp Arg Phe Leu Asp Ser Ile Val Gln Asn Gly 1130 1135 1140 Tyr Gly Leu Ser Asp Arg Tyr Asp Leu Gly Phe Lys Thr Pro Thr 1145 1150 1155 Lys Tyr Gly Thr Asp Gln Asp Leu Arg Lys Ala Ile Glu Arg Leu 1160 1165 1170 His Gln Ala Gly Met Ser Val Met Ala Asp Phe Val Ala Asn Gln 1175 1180 1185 Ile Tyr Gly Leu His Ala Asp Lys Glu Val Val Ser Ala Gln His 1190 1195 1200 Val Asn Ile Asn Gly Asp Thr Lys Leu Val Val Asp Pro Arg Tyr 1205 1210 1215 Gly Thr Gln Met Thr Val Val Asn Ser Val Gly Gly Gly Asp Tyr 1220 1225 1230 Gln Ala Lys Tyr Gly Gly Glu Tyr Leu Asp Thr Ile Ser Lys Leu 1235 1240 1245 Tyr Pro Gly Leu Leu Leu Asp Ser Asn Gly Gln Lys Ile Asp Leu 1250 1255 1260 Ser Thr Lys Ile Lys Glu Trp Ser Ala Lys Tyr Leu Asn Gly Ser 1265 1270 1275 Asn Ile Pro Gln Val Gly Met Gly Tyr Val Leu Lys Asp Trp Asn 1280 1285 1290 Asn Gly Gln Tyr Phe His Ile Leu Asp Lys Glu Gly Gln Tyr Ser 1295 1300 1305 Leu Pro Thr Gln Leu Val Ser Asn Asp Pro Glu Thr Gln Ile Gly 1310 1315 1320 Glu Ser Val Asn Tyr Lys Tyr Phe Ile Gly Asn Ser Asp Ala Thr 1325 1330 1335 Tyr Asn Met Tyr His Asn Leu Pro Asn Thr Val Ser Leu Ile Asn 1340 1345 1350 Ser Gln Glu Gly Gln Ile Lys Thr Gln Gln Ser Gly Val Thr Ser 1355 1360 1365 Asp Tyr Glu Gly Gln Gln Val Gln Val Thr Arg Gln Tyr Thr Asp 1370 1375 1380 Ser Lys Gly Val Ser Trp Asn Leu Ile Thr Phe Ala Gly Gly Asp 1385 1390 1395 Leu Gln Gly Gln Lys Leu Trp Val Asp Ser Arg Ala Leu Thr Met 1400 1405 1410 Thr Pro Phe Lys Thr Met Asn Gln Ile Ser Phe Ile Ser Tyr Ala 1415 1420 1425 Asn Arg Asn Asp Gly Leu Phe Leu Asn Ala Pro Tyr Gln Val Lys 1430 1435 1440 Gly Tyr Gln Leu Ala Gly Met Ser Asn Gln Tyr Lys Gly Gln Gln 1445 1450 1455 Val Thr Ile Ala Gly Val Ala Asn Val Ser Gly Lys Asp Trp Ser 1460 1465 1470 Leu Ile Ser Phe Asn Gly Thr Gln Tyr Trp Ile Asp Ser Gln Ala 1475 1480 1485 Leu Asn Thr Asn Phe Thr His Asp Met Asn Gln Lys Val Phe Val 1490 1495 1500 Asn Thr Thr Ser Asn Leu Asp Gly Leu Phe Leu Asn Ala Pro Tyr 1505 1510 1515 Arg Gln Pro Gly Tyr Lys Leu Ala Gly Leu Ala Lys Asn Tyr Asn 1520 1525 1530 Asn Gln Thr Val Thr Val Ser Gln Gln Tyr Phe Asp Asp Gln Gly 1535 1540 1545 Thr Val Trp Ser Glu Val Val Leu Gly Gly Gln Thr Val Trp Val 1550 1555 1560 Asp Asn His Ala Leu Ala Gln Met Gln Val Ser Asp Thr Ser Gln 1565 1570 1575 Gln Leu Tyr Val Asn Ser Asn Gly Arg Asn Asp Gly Leu Phe Leu 1580 1585 1590 Asn Ala Pro Tyr Arg Gly Gln Gly Ser Gln Leu Ile Gly Met Thr 1595 1600 1605 Ala Asp Tyr Asn Gly Gln His Val Gln Val Thr Lys Gln Gly Gln 1610 1615 1620 Asp Ala Tyr Gly Ala Gln Trp Arg Leu Ile Thr Leu Asn Asn Gln 1625 1630 1635 Gln Val Trp Val Asp Ser Arg Ala Leu Ser Thr Thr Ile Val Gln 1640 1645 1650 Ala Met Asn Asp Asp Met Tyr Val Asn Ser Asn Gln Arg Thr Asp 1655 1660 1665 Gly Leu Trp Leu Asn Ala Pro Tyr Thr Met Ser Gly Ala Lys Trp 1670 1675 1680 Ala Gly Asp Thr Arg Ser Ala Asn Gly Arg Tyr Val His Ile Ser 1685 1690 1695 Lys Ala Tyr Ser Asn Glu Val Gly Asn Thr Tyr Tyr Leu Thr Asn 1700 1705 1710 Leu Asn Gly Gln Ser Thr Trp Ile Asp Lys Arg Ala Phe Thr Ala 1715 1720 1725 Thr Phe Asp Gln Val Val Ala Leu Asn Ala Thr Ile Val Ala Arg 1730 1735 1740 Gln Arg Pro Asp Gly Met Phe Lys Thr Ala Pro Tyr Gly Glu Ala 1745 1750 1755 Gly Ala Gln Phe Val Asp Tyr Val Thr Asn Tyr Asn Gln Gln Thr 1760 1765 1770 Val Pro Val Thr Lys Gln His Ser Asp Ala Gln Gly Asn Gln Trp 1775 1780 1785 Tyr Leu Ala Thr Val Asn Gly Thr Gln Tyr Trp Ile Asp Gln Arg 1790 1795 1800 Ser Phe Ser Pro Val Val Thr Lys Val Val Asp Tyr Gln Ala Lys 1805 1810 1815 Ile Val Pro Arg Thr Thr Arg Asp Gly Val Phe Ser Gly Ala Pro 1820 1825 1830 Tyr Gly Glu Val Asn Ala Lys Leu Val Asn Met Ala Thr Ala Tyr 1835 1840 1845 Gln Asn Gln Val Val His Ala Thr Gly Glu Tyr Thr Asn Ala Ser 1850 1855 1860 Gly Ile Thr Trp Ser Gln Phe Ala Leu Ser Gly Gln Glu Asp Lys 1865 1870 1875 Leu Trp Ile Asp Lys Arg Ala Leu Gln Ala 1880 1885 105667DNALeuconostoc citreum 10atggaaatga aagaaacaat cactcgaaaa aagctgtaca agtcaggtaa aagctgggtt 60gcggctgcta cagcatttgc cgttatgggg gtatctgcgg taacaactgt cagtgccgat 120acacaaacgc cggttggtac aacacagagc caacaggatt tgactggtca gacagggcaa 180gacaagccaa caacgaaaga agttatcgac aaaaaggaac cggttcctca agtatcagca 240caaaacgttg gtgacttgtc agcagatgca aagactccaa aagctgatga taagcaagat 300acgcagccaa caaatgcaca gttacctgat caaggtaaca agcaaacgaa tagtaacagt 360gataagggag taaaggagtc aacaacagct cctgttaaaa cgactgatgt accaagcaag 420tcagtcgcac cagaaaccaa tactagtatt aatggtggcc aatatgtaga aaaagatggc 480caatttgttt atattgatca atctggtaag caggtaagtg gattacaaaa tattgaaggt 540catacgcaat attttgatcc gaaaacaggt tatcaaacta aaggtgaatt aaagaatatt 600gatgataatg cttattattt tgataaaaat agtggcaatg gtcgtacatt tacaaaaatt 660agtaatggta gctattctga aaaagatggc atgtggcagt atgttgatag ccatgacaag 720caaccagtaa agggtctata tgatgttgaa gggaatttac agtattttga cctgtcaaca 780ggtaatcagg ctaaacatca aatacgttca gttgatggtg tcacttatta ttttgacgca 840gacagtggta acgctacggc atttaaagcg gttaccaatg gccgttatgc tgagcagaca 900acgaaagata aagatggcaa tgagacaagt tattgggctt atcttgataa tcaggggaat 960gctatcaaag gtctaaatga cgttaatggc gaaatacaat attttgatga acatactgga 1020gaacaactaa aaggccatac agctacggtt gatgggacaa cgtactattt tgaaggcaat 1080aaaggtaatc tcgtcagtgt tgttaacaca gcaccaacag gtcaatataa aattaacgga 1140gacaatgttt attatcttga caacaataat gaagcaataa agggattata tggcatcaat 1200ggcaatctga attactttga tttagcaacg gggatacaac tcaagggcca agcaaaaaat 1260attgatggta ttggttatta ttttgatcaa aataatggca atggtgagta taggtacagt 1320ttaacaggtc cagtggttaa agacgtttat tctcaacaca atgctgtgaa taatttgagc 1380gcaaataatt ttaagaatct tgtggatggt tttttaacag cagagacctg gtatcgtcca 1440gcacaaattt tgtctcatgg tacagactgg gtagcctcaa ctgataaaga tttcagacca 1500cttattacag tctggtggcc aaacaaggat attcaggtca actatctaaa gttaatgcaa 1560caaatcggta tactagataa ctcagtagta tttgatacaa ataatgatca actagtgtta 1620aataaaggtg ctgagagcgc acaaattggc atcgaaaaaa aggttagtga gacaggcaat 1680acagattggt taaatgagtt gctttttgct cctaacggaa accaaccatc gtttatcaaa 1740caacaatatc tttggaatgt tgattctgaa tatcctggtg gttggtttca gggaggttat 1800ctagcttatc aaaatagtga tttaacacca tatgctaata caaatcctga ttatcgaaca 1860cataatgggt tagagttctt actagccaat gatgttgaca actccaatcc agtcgtacag 1920gctgagcaac tgaactggct atattatttg atgaattttg gccaaattac agcaaatgat 1980tcaaatgcca attttgatag tatgagaatt gatgcaattt catttgttga tccacaaatt 2040gctaaaaaag cttatgacct gttagataaa atgtatggat taactgacaa tgaggcagtt 2100gccaatcaac atatttcaat tgttgaagct ccaaaggggg aaacgccaat taccgttgaa 2160aagcagagtg ccctagttga atcgaactgg cgtgatagga tgaagcaatc attatcaaaa 2220aatgccactc tagataagct agatcctgac cctgctatca attctttgga aaagcttgtc 2280gcagatgatt tagtaaaccg ttcccaaagt tcagataaag acagttcaac gataccaaac 2340tactcgatag ttcatgcaca tgataaagac attcaagaca ctgttattca tatcatgaaa 2400atagttaata acaatccaaa catatctatg agtgacttca caatgcagca attgcaaaat 2460gggttgaaag cattttacga agatcaacac cagtctgtga aaaaatataa ccaatacaat 2520attcctagtg catatgcttt gttgttaacc aataaagata ccgtaccacg agttttttat 2580ggtgacatgt accaagacta tggtgatgat ttagatggtg gtcagtatat ggctacaaaa 2640tcaatttatt ataatgccat tgagcaaatg atgaaggcgc gtttgaagta cgttgctggt 2700ggtcaaataa tggccgtgac aaaaataaaa aatgatggta tcaacaaaga tggtaccaat 2760aagtcaggtg aggttcttac aagcgttcga tttggaaaag atatcatgga cgcacagggc 2820cagggcacag ctgagagtag aaatcagggc attggtgtca tcgtatccaa tagtagcggt 2880cttgagttaa agaatagtga cagtatcacc ttgcatatgg ggattgcaca taaaaatcaa 2940gcataccgag cattaatgct taccaatgat aaagggattg ttaactacga tcaagataat 3000aatgctccga ttgcttggac taatgaccac ggtgatttaa ttttcacgaa tcaaatgatt 3060aacggtcaaa gtgatacggc agttaagggt tatcttaatc ctgaagtcgc aggctactta 3120gccgtttggg taccagttgg cgccaatgac aaccaagatg cgagaactgt gacaacgaat 3180caaaaaaata ctgatggaaa ggtgttgcac acgaatgctg cgcttgattc taaattaatg 3240tatgaagggt tctccaattt ccagaaaatg ccgacacgtg gtaatcagta cgctaatgtg 3300gttattacta aaaatattga tttatttaaa tcatggggaa ttactgattt tgaattagca 3360cctcaatatc gttcaagcga cggaaaagat attaccgacc gttttcttga ctcaattgtt 3420caaaatggtt acggattgag cgatcgctat gacctgggat ttaagacacc cactaagtat 3480ggcacggacc aagacttgcg aaaagcaatt gaaagattac accaggctgg tatgtcagta 3540atggcagatt ttgtagccaa tcaaatttat ggcctacatg ctgataaaga agttgtgtcg 3600gctcagcatg tgaatattaa tggtgataca aagttagtag tagatccacg ctacggcaca 3660caaatgactg ttgttaattc cgttggtggt ggtgattatc aagctaaata tggtggtgag 3720tacttagata ctataagtaa gctttaccct gggttactct tagatagtaa tgggcaaaaa 3780atagatttgt ctacaaaaat taaagaatgg tcagcaaaat atctaaacgg gagcaacatt 3840cctcaagtgg gtatgggtta tgtcttaaaa gattggaaca atggccagta cttccacatt 3900cttgataaag aagggcaata tagcctacca acacaactcg tttctaatga tccagaaaca 3960caaataggtg agagtgtaaa ttataaatac tttattggta actctgatgc aacttataat 4020atgtatcata atctgcctaa taccgttagc cttattaatt ctcaagaagg tcagattaag 4080acacaacagt cgggtgtaac atctgattac gaagggcaac aagtgcaagt cacgcgtcaa 4140tacactgaca gtaagggtgt gagttggaac ttaattacct ttgctggtgg tgatttacaa 4200ggacaaaagc tttgggtgga tagtcgtgcg ttaactatga caccatttaa aacgatgaat 4260caaataagct tcattagtta tgctaaccgc aatgatgggt tgttcttgaa tgcgccatac 4320caagtcaagg ggtatcaatt agctgggatg tccaaccaat acaagggcca acaagtgacc 4380attgccgggg tggcgaacgt ttctggtaaa gactggagtc tgattagttt taatgggaca 4440cagtactgga ttgatagtca ggcattgaat accaatttca cacatgacat gaaccaaaag 4500gtctttgtca atacaactag taatcttgat gggttattct taaatgcgcc ataccgtcaa 4560ccaggttata agttagccgg tttggctaaa aattacaaca accaaacggt taccgttagt 4620caacagtact ttgatgatca aggcacggtc tggagtgagg ttgttcttgg gggtcagacg 4680gtctgggttg ataaccatgc attggcacag atgcaagtca gtgatacaag ccaacagctc 4740tatgtgaata gcaatggtcg taatgatggg ttattcttga atgcgccata tcgtggtcaa 4800gggtcacaac tcataggcat gacggcagat tataatgggc aacatgtaca agtgaccaag 4860caagggcaag atgcctacgg tgcacaatgg cgtcttatta cgctaaataa tcaacaggtc 4920tgggttgata gtcgcgcttt gagcacaaca atcgtgcaag ccatgaatga tgatatgtat 4980gtgaatagca accaacggac agatggtttg tggttaaacg caccttatac gatgagtggg 5040gctaaatggg ctggtgatac gcgttcagct aatgggcgct atgtccatat ttcaaaagct 5100tattcaaacg aagtcggcaa cacatattac ttgacgaatt tgaatggtca aagcacatgg 5160attgacaagc gggcgtttac tgcgaccttt gaccaggtgg tggcattaaa tgcaacgatt 5220gtggcacgcc aacgaccaga tgggatgttt aagacagcac catatggtga agcgggggcg 5280cagtttgtcg attatgtgac aaactataac cagcaaaccg tgccagtaac aaagcaacat 5340tcagatgctc agggtaatca atggtactta gcgacagtga atgggacaca atactggatt 5400gatcaacggt cattttcacc agtagtaacg aaggtggttg attatcaagc taagattgtg 5460ccacggacaa cacgtgatgg tgtgtttagt ggcgcaccct atggggaagt gaatgctaag 5520ctagttaaca tggcaactgc gtatcaaaat caagttgtcc atgcgacagg agaatatacg 5580aatgcttcag ggatcacatg gagtcagttc gcgttaagtg ggcaagaaga caagctatgg 5640attgataagc gtgctttgca agcttaa 5667113822DNAArtificial Sequencedelta PS delta C-1313 11gatacacaaa cgccggttgg tacaacacag agccaacagg atttgactgg tcagacaggg 60caagacaagc caacaacgaa agaagttatc gacaaaaagg aaccggttcc tcaagtatca 120gcacaaaacg ttggtgactt gtcagcagat gcaaagactc caaaagctga tgataagcaa 180gatacgcagc caacaaatgc acagttacct gatcaaggta acaagcaaac gaatagtaac 240agtgataagg gagtaaagga gtcaacaaca gctcctgtta aaacgactga tgtaccaagc 300aagtcagtcg caccagaaac caatactagt attaatggtg gccaatatgt agaaaaagat 360ggccaatttg tttatattga tcaatctggt aagcaggtaa gtggattaca aaatattgaa 420ggtcatacgc aatattttga tccgaaaaca ggttatcaaa ctaaaggtga attaaagaat 480attgatgata atgcttatta ttttgataaa aatagtggca atggtcgtac atttacaaaa 540attagtaatg gtagctattc tgaaaaagat ggcatgtggc agtatgttga tagccatgac 600aagcaaccag taaagggtct atatgatgtt gaagggaatt tacagtattt tgacctgtca 660acaggtaatc aggctaaaca tcaaatacgt tcagttgatg gtgtcactta ttattttgac 720gcagacagtg gtaacgctac ggcatttaaa gcggttacca atggccgtta tgctgagcag 780acaacgaaag ataaagatgg caatgagaca agttattggg cttatcttga taatcagggg 840aatgctatca aaggtctaaa tgacgttaat ggcgaaatac aatattttga tgaacatact 900ggagaacaac taaaaggcca tacagctacg gttgatggga caacgtacta ttttgaaggc 960aataaaggta atctcgtcag tgttgttaac acagcaccaa caggtcaata taaaattaac 1020ggagacaatg tttattatct tgacaacaat aatgaagcaa taaagggatt atatggcatc 1080aatggcaatc tgaattactt tgatttagca acggggatac aactcaaggg ccaagcaaaa 1140aatattgatg gtattggtta ttattttgat caaaataatg gcaatggtga gtataggtac 1200agtttaacag gtccagtggt taaagacgtt tattctcaac acaatgctgt gaataatttg 1260agcgcaaata attttaagaa tcttgtggat ggttttttaa cagcagagac ctggtatcgt 1320ccagcacaaa ttttgtctca tggtacagac tgggtagcct caactgataa agatttcaga 1380ccacttatta cagtctggtg gccaaacaag gatattcagg tcaactatct aaagttaatg 1440caacaaatcg gtatactaga taactcagta gtatttgata caaataatga tcaactagtg 1500ttaaataaag gtgctgagag cgcacaaatt ggcatcgaaa aaaaggttag tgagacaggc 1560aatacagatt ggttaaatga gttgcttttt gctcctaacg gaaaccaacc atcgtttatc 1620aaacaacaat atctttggaa tgttgattct gaatatcctg gtggttggtt tcagggaggt 1680tatctagctt atcaaaatag tgatttaaca ccatatgcta atacaaatcc tgattatcga 1740acacataatg ggttagagtt cttactagcc aatgatgttg acaactccaa tccagtcgta 1800caggctgagc aactgaactg gctatattat ttgatgaatt ttggccaaat tacagcaaat 1860gattcaaatg ccaattttga tagtatgaga attgatgcaa tttcatttgt tgatccacaa 1920attgctaaaa aagcttatga cctgttagat aaaatgtatg gattaactga caatgaggca 1980gttgccaatc aacatatttc aattgttgaa gctccaaagg gggaaacgcc aattaccgtt 2040gaaaagcaga gtgccctagt tgaatcgaac tggcgtgata ggatgaagca atcattatca 2100aaaaatgcca ctctagataa gctagatcct gaccctgcta tcaattcttt ggaaaagctt 2160gtcgcagatg atttagtaaa ccgttcccaa agttcagata aagacagttc aacgatacca 2220aactactcga tagttcatgc acatgataaa gacattcaag acactgttat tcatatcatg 2280aaaatagtta ataacaatcc aaacatatct atgagtgact tcacaatgca gcaattgcaa 2340aatgggttga aagcatttta cgaagatcaa caccagtctg tgaaaaaata taaccaatac 2400aatattccta gtgcatatgc tttgttgtta accaataaag ataccgtacc acgagttttt 2460tatggtgaca tgtaccaaga ctatggtgat gatttagatg gtggtcagta tatggctaca 2520aaatcaattt attataatgc cattgagcaa atgatgaagg cgcgtttgaa gtacgttgct 2580ggtggtcaaa taatggccgt gacaaaaata aaaaatgatg gtatcaacaa agatggtacc 2640aataagtcag gtgaggttct tacaagcgtt cgatttggaa aagatatcat ggacgcacag 2700ggccagggca cagctgagag tagaaatcag ggcattggtg tcatcgtatc caatagtagc 2760ggtcttgagt taaagaatag tgacagtatc accttgcata tggggattgc acataaaaat 2820caagcatacc gagcattaat gcttaccaat gataaaggga ttgttaacta cgatcaagat 2880aataatgctc cgattgcttg gactaatgac cacggtgatt taattttcac gaatcaaatg 2940attaacggtc aaagtgatac ggcagttaag ggttatctta atcctgaagt cgcaggctac 3000ttagccgttt gggtaccagt tggcgccaat gacaaccaag atgcgagaac tgtgacaacg 3060aatcaaaaaa atactgatgg aaaggtgttg cacacgaatg ctgcgcttga ttctaaatta 3120atgtatgaag ggttctccaa tttccagaaa atgccgacac gtggtaatca gtacgctaat 3180gtggttatta ctaaaaatat tgatttattt aaatcatggg gaattactga ttttgaatta 3240gcacctcaat atcgttcaag cgacggaaaa gatattaccg accgttttct tgactcaatt 3300gttcaaaatg gttacggatt gagcgatcgc tatgacctgg gatttaagac acccactaag 3360tatggcacgg accaagactt gcgaaaagca attgaaagat tacaccaggc tggtatgtca 3420gtaatggcag attttgtagc caatcaaatt tatggcctac atgctgataa agaagttgtg 3480tcggctcagc atgtgaatat taatggtgat acaaagttag tagtagatcc acgctacggc 3540acacaaatga ctgttgttaa ttccgttggt ggtggtgatt atcaagctaa

atatggtggt 3600gagtacttag atactataag taagctttac cctgggttac tcttagatag taatgggcaa 3660aaaatagatt tgtctacaaa aattaaagaa tggtcagcaa aatatctaaa cgggagcaac 3720attcctcaag tgggtatggg ttatgtctta aaagattgga acaatggcca gtacttccac 3780attcttgata aagaagggca atatagccta ccaacacaac tc 3822121274PRTArtificial SequenceDelta PS, delta C-1313 12Asp Thr Gln Thr Pro Val Gly Thr Thr Gln Ser Gln Gln Asp Leu Thr 1 5 10 15 Gly Gln Thr Gly Gln Asp Lys Pro Thr Thr Lys Glu Val Ile Asp Lys 20 25 30 Lys Glu Pro Val Pro Gln Val Ser Ala Gln Asn Val Gly Asp Leu Ser 35 40 45 Ala Asp Ala Lys Thr Pro Lys Ala Asp Asp Lys Gln Asp Thr Gln Pro 50 55 60 Thr Asn Ala Gln Leu Pro Asp Gln Gly Asn Lys Gln Thr Asn Ser Asn 65 70 75 80 Ser Asp Lys Gly Val Lys Glu Ser Thr Thr Ala Pro Val Lys Thr Thr 85 90 95 Asp Val Pro Ser Lys Ser Val Ala Pro Glu Thr Asn Thr Ser Ile Asn 100 105 110 Gly Gly Gln Tyr Val Glu Lys Asp Gly Gln Phe Val Tyr Ile Asp Gln 115 120 125 Ser Gly Lys Gln Val Ser Gly Leu Gln Asn Ile Glu Gly His Thr Gln 130 135 140 Tyr Phe Asp Pro Lys Thr Gly Tyr Gln Thr Lys Gly Glu Leu Lys Asn 145 150 155 160 Ile Asp Asp Asn Ala Tyr Tyr Phe Asp Lys Asn Ser Gly Asn Gly Arg 165 170 175 Thr Phe Thr Lys Ile Ser Asn Gly Ser Tyr Ser Glu Lys Asp Gly Met 180 185 190 Trp Gln Tyr Val Asp Ser His Asp Lys Gln Pro Val Lys Gly Leu Tyr 195 200 205 Asp Val Glu Gly Asn Leu Gln Tyr Phe Asp Leu Ser Thr Gly Asn Gln 210 215 220 Ala Lys His Gln Ile Arg Ser Val Asp Gly Val Thr Tyr Tyr Phe Asp 225 230 235 240 Ala Asp Ser Gly Asn Ala Thr Ala Phe Lys Ala Val Thr Asn Gly Arg 245 250 255 Tyr Ala Glu Gln Thr Thr Lys Asp Lys Asp Gly Asn Glu Thr Ser Tyr 260 265 270 Trp Ala Tyr Leu Asp Asn Gln Gly Asn Ala Ile Lys Gly Leu Asn Asp 275 280 285 Val Asn Gly Glu Ile Gln Tyr Phe Asp Glu His Thr Gly Glu Gln Leu 290 295 300 Lys Gly His Thr Ala Thr Val Asp Gly Thr Thr Tyr Tyr Phe Glu Gly 305 310 315 320 Asn Lys Gly Asn Leu Val Ser Val Val Asn Thr Ala Pro Thr Gly Gln 325 330 335 Tyr Lys Ile Asn Gly Asp Asn Val Tyr Tyr Leu Asp Asn Asn Asn Glu 340 345 350 Ala Ile Lys Gly Leu Tyr Gly Ile Asn Gly Asn Leu Asn Tyr Phe Asp 355 360 365 Leu Ala Thr Gly Ile Gln Leu Lys Gly Gln Ala Lys Asn Ile Asp Gly 370 375 380 Ile Gly Tyr Tyr Phe Asp Gln Asn Asn Gly Asn Gly Glu Tyr Arg Tyr 385 390 395 400 Ser Leu Thr Gly Pro Val Val Lys Asp Val Tyr Ser Gln His Asn Ala 405 410 415 Val Asn Asn Leu Ser Ala Asn Asn Phe Lys Asn Leu Val Asp Gly Phe 420 425 430 Leu Thr Ala Glu Thr Trp Tyr Arg Pro Ala Gln Ile Leu Ser His Gly 435 440 445 Thr Asp Trp Val Ala Ser Thr Asp Lys Asp Phe Arg Pro Leu Ile Thr 450 455 460 Val Trp Trp Pro Asn Lys Asp Ile Gln Val Asn Tyr Leu Lys Leu Met 465 470 475 480 Gln Gln Ile Gly Ile Leu Asp Asn Ser Val Val Phe Asp Thr Asn Asn 485 490 495 Asp Gln Leu Val Leu Asn Lys Gly Ala Glu Ser Ala Gln Ile Gly Ile 500 505 510 Glu Lys Lys Val Ser Glu Thr Gly Asn Thr Asp Trp Leu Asn Glu Leu 515 520 525 Leu Phe Ala Pro Asn Gly Asn Gln Pro Ser Phe Ile Lys Gln Gln Tyr 530 535 540 Leu Trp Asn Val Asp Ser Glu Tyr Pro Gly Gly Trp Phe Gln Gly Gly 545 550 555 560 Tyr Leu Ala Tyr Gln Asn Ser Asp Leu Thr Pro Tyr Ala Asn Thr Asn 565 570 575 Pro Asp Tyr Arg Thr His Asn Gly Leu Glu Phe Leu Leu Ala Asn Asp 580 585 590 Val Asp Asn Ser Asn Pro Val Val Gln Ala Glu Gln Leu Asn Trp Leu 595 600 605 Tyr Tyr Leu Met Asn Phe Gly Gln Ile Thr Ala Asn Asp Ser Asn Ala 610 615 620 Asn Phe Asp Ser Met Arg Ile Asp Ala Ile Ser Phe Val Asp Pro Gln 625 630 635 640 Ile Ala Lys Lys Ala Tyr Asp Leu Leu Asp Lys Met Tyr Gly Leu Thr 645 650 655 Asp Asn Glu Ala Val Ala Asn Gln His Ile Ser Ile Val Glu Ala Pro 660 665 670 Lys Gly Glu Thr Pro Ile Thr Val Glu Lys Gln Ser Ala Leu Val Glu 675 680 685 Ser Asn Trp Arg Asp Arg Met Lys Gln Ser Leu Ser Lys Asn Ala Thr 690 695 700 Leu Asp Lys Leu Asp Pro Asp Pro Ala Ile Asn Ser Leu Glu Lys Leu 705 710 715 720 Val Ala Asp Asp Leu Val Asn Arg Ser Gln Ser Ser Asp Lys Asp Ser 725 730 735 Ser Thr Ile Pro Asn Tyr Ser Ile Val His Ala His Asp Lys Asp Ile 740 745 750 Gln Asp Thr Val Ile His Ile Met Lys Ile Val Asn Asn Asn Pro Asn 755 760 765 Ile Ser Met Ser Asp Phe Thr Met Gln Gln Leu Gln Asn Gly Leu Lys 770 775 780 Ala Phe Tyr Glu Asp Gln His Gln Ser Val Lys Lys Tyr Asn Gln Tyr 785 790 795 800 Asn Ile Pro Ser Ala Tyr Ala Leu Leu Leu Thr Asn Lys Asp Thr Val 805 810 815 Pro Arg Val Phe Tyr Gly Asp Met Tyr Gln Asp Tyr Gly Asp Asp Leu 820 825 830 Asp Gly Gly Gln Tyr Met Ala Thr Lys Ser Ile Tyr Tyr Asn Ala Ile 835 840 845 Glu Gln Met Met Lys Ala Arg Leu Lys Tyr Val Ala Gly Gly Gln Ile 850 855 860 Met Ala Val Thr Lys Ile Lys Asn Asp Gly Ile Asn Lys Asp Gly Thr 865 870 875 880 Asn Lys Ser Gly Glu Val Leu Thr Ser Val Arg Phe Gly Lys Asp Ile 885 890 895 Met Asp Ala Gln Gly Gln Gly Thr Ala Glu Ser Arg Asn Gln Gly Ile 900 905 910 Gly Val Ile Val Ser Asn Ser Ser Gly Leu Glu Leu Lys Asn Ser Asp 915 920 925 Ser Ile Thr Leu His Met Gly Ile Ala His Lys Asn Gln Ala Tyr Arg 930 935 940 Ala Leu Met Leu Thr Asn Asp Lys Gly Ile Val Asn Tyr Asp Gln Asp 945 950 955 960 Asn Asn Ala Pro Ile Ala Trp Thr Asn Asp His Gly Asp Leu Ile Phe 965 970 975 Thr Asn Gln Met Ile Asn Gly Gln Ser Asp Thr Ala Val Lys Gly Tyr 980 985 990 Leu Asn Pro Glu Val Ala Gly Tyr Leu Ala Val Trp Val Pro Val Gly 995 1000 1005 Ala Asn Asp Asn Gln Asp Ala Arg Thr Val Thr Thr Asn Gln Lys 1010 1015 1020 Asn Thr Asp Gly Lys Val Leu His Thr Asn Ala Ala Leu Asp Ser 1025 1030 1035 Lys Leu Met Tyr Glu Gly Phe Ser Asn Phe Gln Lys Met Pro Thr 1040 1045 1050 Arg Gly Asn Gln Tyr Ala Asn Val Val Ile Thr Lys Asn Ile Asp 1055 1060 1065 Leu Phe Lys Ser Trp Gly Ile Thr Asp Phe Glu Leu Ala Pro Gln 1070 1075 1080 Tyr Arg Ser Ser Asp Gly Lys Asp Ile Thr Asp Arg Phe Leu Asp 1085 1090 1095 Ser Ile Val Gln Asn Gly Tyr Gly Leu Ser Asp Arg Tyr Asp Leu 1100 1105 1110 Gly Phe Lys Thr Pro Thr Lys Tyr Gly Thr Asp Gln Asp Leu Arg 1115 1120 1125 Lys Ala Ile Glu Arg Leu His Gln Ala Gly Met Ser Val Met Ala 1130 1135 1140 Asp Phe Val Ala Asn Gln Ile Tyr Gly Leu His Ala Asp Lys Glu 1145 1150 1155 Val Val Ser Ala Gln His Val Asn Ile Asn Gly Asp Thr Lys Leu 1160 1165 1170 Val Val Asp Pro Arg Tyr Gly Thr Gln Met Thr Val Val Asn Ser 1175 1180 1185 Val Gly Gly Gly Asp Tyr Gln Ala Lys Tyr Gly Gly Glu Tyr Leu 1190 1195 1200 Asp Thr Ile Ser Lys Leu Tyr Pro Gly Leu Leu Leu Asp Ser Asn 1205 1210 1215 Gly Gln Lys Ile Asp Leu Ser Thr Lys Ile Lys Glu Trp Ser Ala 1220 1225 1230 Lys Tyr Leu Asn Gly Ser Asn Ile Pro Gln Val Gly Met Gly Tyr 1235 1240 1245 Val Leu Lys Asp Trp Asn Asn Gly Gln Tyr Phe His Ile Leu Asp 1250 1255 1260 Lys Glu Gly Gln Tyr Ser Leu Pro Thr Gln Leu 1265 1270 134244DNALeuconostoc citreum 13atggaaatga aagaaacaat cactcgaaaa aagctgtaca agtcaggtaa aagctgggtt 60gcggctgcta cagcatttgc cgttatgggg gtatctgcgg taacaactgt cagtgccgat 120acacaaacgc cggttggtac aacacagagc caacagaatt tgactggtca gacagggcaa 180gacaagccaa caacgaaaga agttatcgac aaaaaggaac cggttcccca ggtatcagca 240caaaatgctg gtgacttgtc agcagatgca aagactccaa aagctgatga taagcaagat 300acgcagccaa caaatgcaca gttacctgat caaggtaaca agcaaacgaa tagtaacagt 360gataagggag taaaggagtc aacaacagct cctgttaaaa cgactgatgt accaagcaag 420tcagtcacac cagaaacaaa tactagtatt aatggtggac aatatgtaga aaaagatggc 480caatttgttt atattgatca atctggtaag caggtaagtg gattacaaaa tattgaaggt 540catacgcaat attttgatcc gaaaacaggt tatcaaacta aaggtgaatt aaagaatatt 600gatgataatg cttattattt tgataaaaat agtggcaatg gtcgtacatt tacaaaaatt 660agtaatggta gctattctga aaaagatggc atgtggcagt atgttgatag ccatgacaag 720caaccagtaa agggtctata tgatgttgaa gggaatttac agtattttga cctgtcaaca 780ggtaatcagg ctaaacatca aatacgttca gttgatggtg tcacttatta tttcgacgca 840gacagtggta acgctacggc atttaaagcg gttaccaatg gccgttatgc tgagcagaca 900acgaaagata aagatggcaa tgagacaagt tattgggctt atcttgataa tcaggggaat 960gctgtcaaag gtctaaatga cgtcaatggt gaaatacagt actttgatga aatcgctggc 1020gcacagctaa aaggtcacac agctacggtt gatggtgtca cttactattt tgaaagcaat 1080aaaggaaatc tcgtaagtgt tgttaacgca gcgccgacag gacaatataa aatagatggt 1140gataaagtat actatcttga taatcaaaat caaccattaa agggattgta tagtatcaat 1200ggcaatctga attactttga tttagccacg gggatacaag tcaaaggtca ggcagaaaac 1260atcaatggta ttggttatta ttttgatcaa aataatggca atggtgagta taggtacagt 1320ttaacaggtc cagtggttaa agacgtttat tctcaacaca atgctgtgaa taatttgagc 1380gcaaataatt ttaggaatct tgtggatggt ttcttaacag cagagacctg gtatcgtcca 1440gcacaaattt tgtctcaggg taaagactgg gtagcctcaa ctgataaaga tttcagacca 1500cttattacag tctggtggcc aaacaaggat attcaggtca actatctaaa gttaatgcaa 1560caaatcggta tagtagataa ctcagtagta tttgatacaa ataatgatca actagtgtta 1620aataaaggtg ctgagagcgc acaaattggc atcgaaaaaa aggttagcga gacaggcaat 1680acagattggt taaatgagtt gctttttgct cctaacggaa accaaccatc gtttatcaaa 1740caacaatatc tttggaatgt tgattctgaa tatcctggtg gttggtttca gggaggttat 1800ctatcttatc aaaatagtga tttaacacca tatgctaata caaatcctga ttatcgaaca 1860cataatgggt tagagttctt actagccaat gatgttgaca actccaatcc agtcgtacag 1920gctgagcaac tgaactggct atattatttg atgaattttg gccaaattac agcaaatgat 1980tcaaatgcca attttgatag tatgagaatt gatgcaattt catttgttga tccacaaatt 2040gctaaaaaag cttatgacct gttagataaa atgtatggat taactgacaa tgaggcagtt 2100gccaatcaac atatttcaat tgttgaagct ccaaaggggg aaacgccaat taccgttgaa 2160aagcagagtg ccctagttga atcgaactgg cgtgatagga tgaagcaatc attatcaaaa 2220aatgccactc tagataagct agatcctgac cctgctatca attctttgga aaagcttgtc 2280gcagatgatt tagtaaaccg ttcccaaagt tcagataaag acagttcaac gataccaaac 2340tactcgatag ttcatgcaca tgataaagac attcaagaca ctgttattca tatcatgaaa 2400atagttaata acaatccaaa catatctatg agtgacttca caatgcagca attgcaaaat 2460gggttgaaag cattttacga agatcaacac cagtctgtga aaaaatataa ccaatacaat 2520attcctagtg catatgcttt gttgttaacc aataaagata ccgtaccacg agttttttat 2580ggtgacatgt accaagacta tggtgatgat ttagatggtg gtcagtatat ggctacaaaa 2640tcaatttatt ataatgccat tgagcaaatg atgaaggcgc gtttgaagta cgttgctggt 2700ggtcaaataa tggccgtgac aaaaataaaa aatgatggta tcaacaaaga tggtaccaat 2760aagtcaggtg aggttcttac aagcgttcga tttggaaaag atatcatgga cgcacagggc 2820cagggcacag ctgagagtag aaatcagggc attggtgtca tcgtatccaa tagtagcggt 2880cttgagttaa agaatagtga cagtatcacc ttgcatatgg ggattgcaca taaaaatcaa 2940gcataccgag cattaatgct taccaatgat aaagggattg ttaactacga tcaagataat 3000aatgctccga ttgcttggac taatgaccac ggtgatttaa ttttcacgaa tcaaatgatt 3060aacggtcaaa gtgatacggc agttaagggt tatcttaatc ctgaagtcgc aggctactta 3120gccgtttggg taccagttgg cgccaatgac aaccaagatg cgagaactgt gacaacgaat 3180caaaaaaata ctgatggaaa ggtgttgcac acgaatgctg cgcttgattc taaattaatg 3240tatgaagggt tctccaattt ccagaaaatg ccgacacgtg gtaatcagta cgctaatgtg 3300attattgcta aaaatattga tttatttaaa tcatggggaa ttactgattt tgaattagca 3360cctcaatatc gttcaagcga cggaaaagat attaccgacc gttttcttga ctcaattgtt 3420caaaatggtt acggattgag cgatcgctat gacctgggat ttaagacacc cactaagtat 3480ggcacggacc aagacttgcg aaaagcaatt gaaagattac accaggctgg tatgtcagta 3540atggcagatt ttgtagccaa tcaaatttat ggcctacatg ctgataaaga agttgtgtcg 3600gctcagcatg tgaatattaa tggtgataca aagttagtag tagatccacg ctacggcaca 3660caaatgactg ttgttaattc cgttggtggt ggtgattatc aagctaaata tggtggtgag 3720tacttagata ctataagtaa gctttaccct gggttactct tagatagtaa tgggcaaaaa 3780atagatttgt ctacaaaaat taaagaatgg tcagcaaaat atctaaacgg gagcaatatt 3840cctcaagtgg gtatgggtta tgtcttaaaa gattggaaca atggccagta cttccacatt 3900cttgataaag aagggcaata tagcctacca acacaactcg tttctaatga tccagaaaca 3960caaataggtg agagtgtaaa ttataaatac tttattggta actctgatgc aacttataat 4020atgtatcata atctgcctaa taccgttagc cttattaatt ctcaagaagg tcagattaag 4080acacaacagt cgggtgtaac atctgattac gaagggcaac aagtgcaagt cacgcgccag 4140tacacagata gtaagggtgt gagttggaac ttaattacct ttgctggtgg tgatttacaa 4200ggacaaaagc tttgggtgga tagtcgtgcg ttaactatga cacc 4244141611PRTLeuconostoc citreum 14Met Glu Met Lys Glu Thr Ile Thr Arg Lys Lys Leu Tyr Lys Ser Gly 1 5 10 15 Lys Ser Trp Val Ala Ala Ala Thr Ala Phe Ala Val Met Gly Val Ser 20 25 30 Ala Val Thr Thr Val Ser Ala Asp Thr Gln Thr Pro Val Gly Thr Thr 35 40 45 Gln Ser Gln Gln Asn Leu Thr Gly Gln Thr Gly Gln Asp Lys Pro Thr 50 55 60 Thr Lys Glu Val Ile Asp Lys Lys Glu Pro Val Pro Gln Val Ser Ala 65 70 75 80 Gln Asn Ala Gly Asp Leu Ser Ala Asp Ala Lys Thr Pro Lys Ala Asp 85 90 95 Asp Lys Gln Asp Thr Gln Pro Thr Asn Ala Gln Leu Pro Asp Gln Gly 100 105 110 Asn Lys Gln Thr Asn Ser Asn Ser Asp Lys Gly Val Lys Glu Ser Thr 115 120 125 Thr Ala Pro Val Lys Thr Thr Asp Val Pro Ser Lys Ser Val Thr Pro 130 135 140 Glu Thr Asn Thr Ser Ile Asn Gly Gly Gln Tyr Val Glu Lys Asp Gly 145 150 155 160 Gln Phe Val Tyr Ile Asp Gln Ser Gly Lys Gln Val Ser Gly Leu Gln 165 170 175 Asn Ile Glu Gly His Thr Gln Tyr Phe Asp Pro Lys Thr Gly Tyr Gln 180 185 190 Thr Lys Gly Glu Leu Lys Asn Ile Asp Asp Asn Ala Tyr Tyr Phe Asp 195 200 205 Lys Asn Ser Gly Asn Gly Arg Thr Phe Thr Lys Ile Ser Asn Gly Ser 210 215 220 Tyr Ser Glu Lys Asp Gly Met Trp Gln Tyr Val Asp Ser His Asp Lys 225 230 235 240 Gln Pro Val Lys Gly Leu Tyr Asp Val Glu Gly Asn Leu Gln Tyr Phe 245 250 255 Asp Leu Ser Thr Gly Asn Gln Ala Lys His Gln Ile Arg Ser Val Asp 260 265 270 Gly Val Thr Tyr Tyr Phe Asp Ala Asp Ser Gly Asn Ala Thr Ala Phe 275 280 285 Lys Ala Val Thr Asn Gly Arg Tyr Ala Glu Gln Thr Thr Lys Asp Lys 290 295 300 Asp Gly Asn Glu Thr Ser Tyr Trp Ala Tyr Leu Asp Asn Gln Gly Asn 305

310 315 320 Ala Val Lys Gly Leu Asn Asp Val Asn Gly Glu Ile Gln Tyr Phe Asp 325 330 335 Glu Ile Ala Gly Ala Gln Leu Lys Gly His Thr Ala Thr Val Asp Gly 340 345 350 Val Thr Tyr Tyr Phe Glu Ser Asn Lys Gly Asn Leu Val Ser Val Val 355 360 365 Asn Ala Ala Pro Thr Gly Gln Tyr Lys Ile Asp Gly Asp Lys Val Tyr 370 375 380 Tyr Leu Asp Asn Gln Asn Gln Pro Leu Lys Gly Leu Tyr Ser Ile Asn 385 390 395 400 Gly Asn Leu Asn Tyr Phe Asp Leu Ala Thr Gly Ile Gln Val Lys Gly 405 410 415 Gln Ala Glu Asn Ile Asn Gly Ile Gly Tyr Tyr Phe Asp Gln Asn Asn 420 425 430 Gly Asn Gly Glu Tyr Arg Tyr Ser Leu Thr Gly Pro Val Val Lys Asp 435 440 445 Val Tyr Ser Gln His Asn Ala Val Asn Asn Leu Ser Ala Asn Asn Phe 450 455 460 Arg Asn Leu Val Asp Gly Phe Leu Thr Ala Glu Thr Trp Tyr Arg Pro 465 470 475 480 Ala Gln Ile Leu Ser Gln Gly Lys Asp Trp Val Ala Ser Thr Asp Lys 485 490 495 Asp Phe Arg Pro Leu Ile Thr Val Trp Trp Pro Asn Lys Asp Ile Gln 500 505 510 Val Asn Tyr Leu Lys Leu Met Gln Gln Ile Gly Ile Val Asp Asn Ser 515 520 525 Val Val Phe Asp Thr Asn Asn Asp Gln Leu Val Leu Asn Lys Gly Ala 530 535 540 Glu Ser Ala Gln Ile Gly Ile Glu Lys Lys Val Ser Glu Thr Gly Asn 545 550 555 560 Thr Asp Trp Leu Asn Glu Leu Leu Phe Ala Pro Asn Gly Asn Gln Pro 565 570 575 Ser Phe Ile Lys Gln Gln Tyr Leu Trp Asn Val Asp Ser Glu Tyr Pro 580 585 590 Gly Gly Trp Phe Gln Gly Gly Tyr Leu Ser Tyr Gln Asn Ser Asp Leu 595 600 605 Thr Pro Tyr Ala Asn Thr Asn Pro Asp Tyr Arg Thr His Asn Gly Leu 610 615 620 Glu Phe Leu Leu Ala Asn Asp Val Asp Asn Ser Asn Pro Val Val Gln 625 630 635 640 Ala Glu Gln Leu Asn Trp Leu Tyr Tyr Leu Met Asn Phe Gly Gln Ile 645 650 655 Thr Ala Asn Asp Ser Asn Ala Asn Phe Asp Ser Met Arg Ile Asp Ala 660 665 670 Ile Ser Phe Val Asp Pro Gln Ile Ala Lys Lys Ala Tyr Asp Leu Leu 675 680 685 Asp Lys Met Tyr Gly Leu Thr Asp Asn Glu Ala Val Ala Asn Gln His 690 695 700 Ile Ser Ile Val Glu Ala Pro Lys Gly Glu Thr Pro Ile Thr Val Glu 705 710 715 720 Lys Gln Ser Ala Leu Val Glu Ser Asn Trp Arg Asp Arg Met Lys Gln 725 730 735 Ser Leu Ser Lys Asn Ala Thr Leu Asp Lys Leu Asp Pro Asp Pro Ala 740 745 750 Ile Asn Ser Leu Glu Lys Leu Val Ala Asp Asp Leu Val Asn Arg Ser 755 760 765 Gln Ser Ser Asp Lys Asp Ser Ser Thr Ile Pro Asn Tyr Ser Ile Val 770 775 780 His Ala His Asp Lys Asp Ile Gln Asp Thr Val Ile His Ile Met Lys 785 790 795 800 Ile Val Asn Asn Asn Pro Asn Ile Ser Met Ser Asp Phe Thr Met Gln 805 810 815 Gln Leu Gln Asn Gly Leu Lys Ala Phe Tyr Glu Asp Gln His Gln Ser 820 825 830 Val Lys Lys Tyr Asn Gln Tyr Asn Ile Pro Ser Ala Tyr Ala Leu Leu 835 840 845 Leu Thr Asn Lys Asp Thr Val Pro Arg Val Phe Tyr Gly Asp Met Tyr 850 855 860 Gln Asp Tyr Gly Asp Asp Leu Asp Gly Gly Gln Tyr Met Ala Thr Lys 865 870 875 880 Ser Ile Tyr Tyr Asn Ala Ile Glu Gln Met Met Lys Ala Arg Leu Lys 885 890 895 Tyr Val Ala Gly Gly Gln Ile Met Ala Val Thr Lys Ile Lys Asn Asp 900 905 910 Gly Ile Asn Lys Asp Gly Thr Asn Lys Ser Gly Glu Val Leu Thr Ser 915 920 925 Val Arg Phe Gly Lys Asp Ile Met Asp Ala Gln Gly Gln Gly Thr Ala 930 935 940 Glu Ser Arg Asn Gln Gly Ile Gly Val Ile Val Ser Asn Ser Ser Gly 945 950 955 960 Leu Glu Leu Lys Asn Ser Asp Ser Ile Thr Leu His Met Gly Ile Ala 965 970 975 His Lys Asn Gln Ala Tyr Arg Ala Leu Met Leu Thr Asn Asp Lys Gly 980 985 990 Ile Val Asn Tyr Asp Gln Asp Asn Asn Ala Pro Ile Ala Trp Thr Asn 995 1000 1005 Asp His Gly Asp Leu Ile Phe Thr Asn Gln Met Ile Asn Gly Gln 1010 1015 1020 Ser Asp Thr Ala Val Lys Gly Tyr Leu Asn Pro Glu Val Ala Gly 1025 1030 1035 Tyr Leu Ala Val Trp Val Pro Val Gly Ala Asn Asp Asn Gln Asp 1040 1045 1050 Ala Arg Thr Val Thr Thr Asn Gln Lys Asn Thr Asp Gly Lys Val 1055 1060 1065 Leu His Thr Asn Ala Ala Leu Asp Ser Lys Leu Met Tyr Glu Gly 1070 1075 1080 Phe Ser Asn Phe Gln Lys Met Pro Thr Arg Gly Asn Gln Tyr Ala 1085 1090 1095 Asn Val Ile Ile Ala Lys Asn Ile Asp Leu Phe Lys Ser Trp Gly 1100 1105 1110 Ile Thr Asp Phe Glu Leu Ala Pro Gln Tyr Arg Ser Ser Asp Gly 1115 1120 1125 Lys Asp Ile Thr Asp Arg Phe Leu Asp Ser Ile Val Gln Asn Gly 1130 1135 1140 Tyr Gly Leu Ser Asp Arg Tyr Asp Leu Gly Phe Lys Thr Pro Thr 1145 1150 1155 Lys Tyr Gly Thr Asp Gln Asp Leu Arg Lys Ala Ile Glu Arg Leu 1160 1165 1170 His Gln Ala Gly Met Ser Val Met Ala Asp Phe Val Ala Asn Gln 1175 1180 1185 Ile Tyr Gly Leu His Ala Asp Lys Glu Val Val Ser Ala Gln His 1190 1195 1200 Val Asn Ile Asn Gly Asp Thr Lys Leu Val Val Asp Pro Arg Tyr 1205 1210 1215 Gly Thr Gln Met Thr Val Val Asn Ser Val Gly Gly Gly Asp Tyr 1220 1225 1230 Gln Ala Lys Tyr Gly Gly Glu Tyr Leu Asp Thr Ile Ser Lys Leu 1235 1240 1245 Tyr Pro Gly Leu Leu Leu Asp Ser Asn Gly Gln Lys Ile Asp Leu 1250 1255 1260 Ser Thr Lys Ile Lys Glu Trp Ser Ala Lys Tyr Leu Asn Gly Ser 1265 1270 1275 Asn Ile Pro Gln Val Gly Met Gly Tyr Val Leu Lys Asp Trp Asn 1280 1285 1290 Asn Gly Gln Tyr Phe His Ile Leu Asp Lys Glu Gly Gln Tyr Ser 1295 1300 1305 Leu Pro Thr Gln Leu Val Ser Asn Asp Pro Glu Thr Gln Ile Gly 1310 1315 1320 Glu Ser Val Asn Tyr Lys Tyr Phe Ile Gly Asn Ser Asp Ala Thr 1325 1330 1335 Tyr Asn Met Tyr His Asn Leu Pro Asn Thr Val Ser Leu Ile Asn 1340 1345 1350 Ser Gln Glu Gly Gln Ile Lys Thr Gln Gln Ser Gly Val Thr Ser 1355 1360 1365 Asp Tyr Glu Gly Gln Gln Val Gln Val Thr Arg Gln Tyr Thr Asp 1370 1375 1380 Ser Lys Gly Val Ser Trp Asn Leu Ile Thr Phe Ala Gly Gly Asp 1385 1390 1395 Leu Gln Gly Gln Lys Leu Trp Val Asp Ser Arg Ala Leu Thr Met 1400 1405 1410 Thr Pro Phe Lys Thr Met Asn Gln Ile Ser Phe Ile Ser Tyr Ala 1415 1420 1425 Asn Arg Asn Asp Gly Leu Phe Leu Asn Ala Pro Tyr Gln Val Lys 1430 1435 1440 Gly Tyr Gln Leu Ala Gly Met Ser Asn Gln Tyr Lys Gly Gln Gln 1445 1450 1455 Val Thr Ile Ala Gly Val Ala Asn Val Ser Gly Lys Asp Trp Ser 1460 1465 1470 Leu Ile Ser Phe Asn Gly Thr Gln Tyr Trp Ile Asp Ser Gln Ala 1475 1480 1485 Leu Asn Thr Asn Phe Thr His Asp Met Asn Gln Lys Val Phe Val 1490 1495 1500 Asn Thr Thr Ser Asn Leu Asp Gly Leu Phe Leu Asn Ala Pro Tyr 1505 1510 1515 Arg Gln Pro Gly Tyr Lys Leu Ala Gly Leu Ala Lys Asn Tyr Asn 1520 1525 1530 Asn Gln Thr Val Thr Val Ser Gln Gln Tyr Phe Asp Asp Gln Gly 1535 1540 1545 Thr Val Trp Ser Gln Val Val Leu Gly Gly Gln Thr Val Trp Val 1550 1555 1560 Asp Asn His Ala Leu Ala Gln Met Gln Val Ser Asp Thr Ser Gln 1565 1570 1575 Gln Leu Tyr Val Asn Ser Asn Gly Arg Asn Asp Gly Leu Phe Leu 1580 1585 1590 Asn Ala Pro Tyr Arg Gly Gln Gly Ser Gln Leu Ile Gly Met Thr 1595 1600 1605 Ala Asp Tyr 1610 155322DNAArtificial Sequenceoptimised Leuconostoc fallax AN optimised sequence 15atgaagcagc aagagagcat cactcgtaag aagctgtaca aggcgggcaa aagctgggta 60gtcgcagcaa ctctgttcgc tgcaactctg tttgctgcaa tgggtgctgc tggtgcaact 120actgttgcat ctgcagacgt acaaaaggat actgtagtgg taaccgcaga taagaacacc 180accgataagg acaaggagcc aatcaagacc gcaggtgcta acgtagtcga taagggtgta 240gcacaaacta ccgataccaa caccaccgac aaaaagacca tcgaggtcgg taaaagcgtc 300gatatgagcg caactgacaa gaaggtgacc gagactgtca agagcgtaga cactagcgct 360actgacaaga aaacgacgga ggcagttaag cctgtcgata ctaacgctac cgataagaag 420gctaccgagg ctgttaagcc tgtagatact aacgcaaccg ataagaaaac caccgaggca 480gtgaagcctg tcgacactaa cactacggac aagaaggtca ctgaggcaat caaaccggtc 540aacactaacg cagacgataa aaccgccgag cctgttaaga ctatcagcgc aactaaagac 600acggtcaaaa ccatcgcgaa caaacagaaa ggtgccacgg aggagcaagc agtcatcact 660gagggtcatt acgaggcaca aggtgacggt tttgtctaca tcactaaaga cggcaaacag 720ctgaccggtc tgcaaaacat caacggtaac acccagtact tcgatccggc aactggtcaa 780caactgaaag gcgatatcaa agccgtggct ggtactgtct actacttcga caaaaacagc 840ggcaacgcac gtgtctacca aaaagtcgcc gatggtactt acagcgagaa caacgaacac 900tggcaataca tcagcaaagt cgacaacaaa ccagtggaag gtctgtacaa cgtgcagggt 960aacctgcagt acttcgacat gagcaccggt aaccaggtca aaaacgacat ccgtagcgtg 1020gacggtgtga cttactactt tgacaaagac agcggtaacg gctccgcttt caacgcactg 1080agcgcaggtg aatacgttga gaaaaaagaa accgacgcac agggtaacca aaacagctac 1140tggacgtaca gcggtctgga tggtaaccct gttaagggtc tgtacgatat caacggttcc 1200ctgcaatact tcgacgagaa aaacggcgca cagctgaaag gtggtactgc aactgtgaac 1260ggtgtgacgt actacttcga acaggataaa ggcaacctga tcagcgtggt caacagcgtg 1320gaaagcggtc aatacaaaat cgacaacgac aacgtgtact acatcgacaa ccagggcaac 1380accctgaaag gtctgtacgc tatcaacggt cagctgaact atttcgacat gtccacgggt 1440gtgcaactga aaggtgcaag cgaaaacgct aacggtgtgg gttactattt cgataaagac 1500aaaggcaacg gccagtacca gtacagcctg atcacgtcca ccctggcaaa cgctttcagc 1560aaacacaacg cagcaaacga ttacacgcag agcagcttca ctcataccgt ggatggtttc 1620ctgactgctg atacttggta ccgtccaact gaaatcctga aaaacggcac cacctgggtg 1680gcatctacta gccaagatct gcgtccaatg atcactgtgt ggtggccaaa caaaaacgtg 1740caactgaact acctgaaact gatgcagacc gaaggtctgc tggattctgg tcaagtgtac 1800gacctgaact ctgaccaagc actgctgaac caggctgctc agactgttca ggtaaacatc 1860gaaaaacgta tcaccaaagc cggtaactcc gactggctga acgatctgct gtacaactct 1920cacggtgaaa ctccatcttt cgtgaaacag caggctatct ggaacgctga ctctgaatac 1980cacggtggtt ggttccaggg tggttatctg gcttaccgta actctgacct gactccgtat 2040gctaactctt cttaccgtca ttacacgggt atggaatttc tgctggccaa cgacgtggac 2100aactctaacc cgatcgtgca ggctgaagat ctgaactggc tgtattacct gatgaacttc 2160ggcactgaaa cgggtaacga cccgcaagct aatttcgact ctatccgtat cgacgctatc 2220tctttcgtgg acaaacaggt ggctaaaaaa gcgtacgaac tgctgcacga catgtacggt 2280ctgtctgctt ctgacgctgt ggctaacaaa cacgtgtcta tcgtggaagc ttctgctgac 2340cagactccgg ttactactga aaaccacgac gctctgatcg aatcttactg gcgtgacact 2400atgaaaaact ccctgtccaa agacgcgtct atcgactcct ctgctggttc tctgtctgct 2460atgatcaacg acggtaacgt ggaccgtgct aatgactcta ctactgaatc ctccatcttc 2520ccgaactaca ccatcgtgca tgctcatgac aaagacatcc aggacgctgt gtctaacgtg 2580atgaaaatcg tgaacaacga cccgtccatc tccctggacg gtttcactat ggaacagctg 2640gaaaaaggcc tgtctgcttt ctacgcggat cagcgttctg ctgtaaaaca gtacaaccag 2700tacaacatcc cgtccgcgta tgcggttatg ctgactaaca aagacaccgt gccgcgtact 2760ttctacggcg atatgtacca ggatgacggt cagtatatgg cgaacaaatc cctgtactac 2820gacgcgatcg ataccatgat gaaagcccgt ctgaaatacg tttccggtgg tcagaccatg 2880tctgttacga aaatcaacaa tgccaactcc cagaaatccg gcgaagttct gacctccgtt 2940cgtttcggta aaggcgttat ggacgcgacc gatgccggtt ctgcggaatc tcgtacccag 3000ggtattggtg ttgttgtatc taactcttct ggtctgcagc tgaatgacaa cgacaaaatc 3060gttctgcaca tgggtgccgc gcataaaaac caggaatacc gtgcgctgat gctgaccacg 3120aatgatggta ttaagtcttt caacaacgac gaagcgccga tcaactacac cgacgacaac 3180ggcgatctga ttttcgacgg tcataacatc gacggtcagg aaaacaccgc gattcgtggt 3240tacctgaacc cgcaggttgc cggttatctg gcggtttggg ttccgacggg tgccaaagat 3300gatcaggatg cgcgtaccca gccgtctaat gaaaaatcta ccgatggtaa agttctgcat 3360accaatgcgg ccctggattc tgaactgatc tatgaaggtt tttctaattt ccagccgatg 3420ccgaccacca aagatgaata taccaacgtt atgatcgcga aaaacattga cctgttcaaa 3480tcctggggca ttaccaactt cgaactggcg ccgcagtacc gttcttccga cggtaaaaac 3540attaacgacc gcttcattga ctccctggtg cagaacggtt acggtctgtc cgatcgttac 3600gacctgggtt ttgaaacccc gaccaaatac ggcaccgatc aggatctgcg taccgccatt 3660aagaccctgc accaggcggg catgaccgta atggccgatt atgttgcgaa tcagatctat 3720ggcctgaata cctctcagga agttgtagat gcccagcgtg taaattctga taataatgcg 3780gtagaagtac gttacggcca gcacctgaat gttgtaaact ctattggcgg tggcgaatat 3840cagaacctgt acggcggcaa atatctggaa attctgaaca aactgtaccc ggacctgctg 3900gtagacgaaa acggcaacaa gattgacatt gacaccaaaa tcaaacagtg gtccgcgaaa 3960tacctgaacg gctccaacgt gaccggcctg ggcatgggct atgttctgaa agattggtct 4020aacggccagt atttcaacat ctccaacacc gacggcaaag ttatgctgcc ggaacagctg 4080gtaaaacaca tgccggcggt tgaaatcggc acccagacca attataccgc gtatatttct 4140tccaccattc gtcgtgacgg cctgtataac aacatgccgt ggggcgttac ggcgaccggc 4200caggatggca atgaaattaa gtgggaacgt cagggctcta cctccgatta taatcaccag 4260aaagttcagg ttaatcgtca gtatgttgac aaacagggcg tagtttggaa cctgattaac 4320ttcgatgata aagatctgtg ggttgactcc aacgcgctgg tgacggtaaa cttcacctcc 4380cagaaaccga ccaaacactt cgtacagttc ggcatgcgtc agggcaaata cgatggcttt 4440tacctgagcg cgccgtacaa acagaccgaa tctaaatggg ttgcgtctac ccgtacccac 4500cagggccagc tgctggaagt tgttggccag tataccaccg gctccggcag ccgcaaagtt 4560acctggtatc tggttggcct ggatggcaaa caggtttggg ttgatagccg cgccgttggc 4620acgaatttta gccacaaaac caatattaat ctgctgatta attccgcgac ccgcaatgat 4680ggcatgtatc tgaatgcccc gtatggccag aaaggctaca aacgcgaaac cagctcccgc 4740ttttataatg aaaaactggt taccgtttcc cagcagtatt atgataacaa aggcgttatt 4800tggaatctga ttaccctgaa cggcaaaaaa ctgtgggttg attcccgcgc ctttgcgacg 4860gttattgata aaaaagttaa ccagtccctg tacattaaca gccgcaacga tggtatgtat 4920ctgaacgccc cgtatcgcgc gcagggcgcg aaacgctatg cgtccaccaa aacctatacc 4980ggccagcgcg tacaggtaac cctgcagcgc aaagataccc acggcgttac gtggtatctg 5040accaaagttg atagcaaaca gctgtgggta gattcccacg cgtttgcgcc gacgtttacc 5100cgcaacgtta gcctgaacgt taaagttaac tccagcaaac gcaacgatgg catctatctg 5160aacgcgccgt atggcaacaa aaaagcgaaa cgcattgcga gcaccaaagc gtataacggc 5220aaacgcgtta aagcctccaa agaatacaaa gatgcgaaag gcgtaacctg gtacctggtt 5280aacctgaaca acaaacaggt atggattgat aaacgtgcgt tt 5322161774PRTLeuconostoc fallax 16Met Lys Gln Gln Glu Ser Ile Thr Arg Lys Lys Leu Tyr Lys Ala Gly 1 5 10 15 Lys Ser Trp Val Val Ala Ala Thr Leu Phe Ala Ala Thr Leu Phe Ala 20 25 30 Ala Met Gly Ala Ala Gly Ala Thr Thr Val Ala Ser Ala Asp Val Gln 35 40 45 Lys Asp Thr Val Val Val Thr Ala Asp Lys Asn Thr Thr Asp Lys Asp 50 55 60 Lys Glu Pro Ile Lys Thr Ala Gly Ala Asn Val Val Asp Lys Gly Val 65 70 75 80 Ala Gln Thr Thr Asp Thr Asn Thr Thr Asp Lys Lys Thr Ile Glu Val 85 90 95 Gly Lys Ser Val Asp Met Ser Ala Thr Asp Lys Lys Val Thr Glu Thr 100 105 110 Val Lys Ser Val Asp Thr Ser Ala Thr Asp Lys Lys Thr Thr Glu Ala 115 120 125 Val Lys Pro Val Asp Thr Asn Ala Thr Asp Lys Lys Ala Thr Glu Ala 130 135 140

Val Lys Pro Val Asp Thr Asn Ala Thr Asp Lys Lys Thr Thr Glu Ala 145 150 155 160 Val Lys Pro Val Asp Thr Asn Thr Thr Asp Lys Lys Val Thr Glu Ala 165 170 175 Ile Lys Pro Val Asn Thr Asn Ala Asp Asp Lys Thr Ala Glu Pro Val 180 185 190 Lys Thr Ile Ser Ala Thr Lys Asp Thr Val Lys Thr Ile Ala Asn Lys 195 200 205 Gln Lys Gly Ala Thr Glu Glu Gln Ala Val Ile Thr Glu Gly His Tyr 210 215 220 Glu Ala Gln Gly Asp Gly Phe Val Tyr Ile Thr Lys Asp Gly Lys Gln 225 230 235 240 Leu Thr Gly Leu Gln Asn Ile Asn Gly Asn Thr Gln Tyr Phe Asp Pro 245 250 255 Ala Thr Gly Gln Gln Leu Lys Gly Asp Ile Lys Ala Val Ala Gly Thr 260 265 270 Val Tyr Tyr Phe Asp Lys Asn Ser Gly Asn Ala Arg Val Tyr Gln Lys 275 280 285 Val Ala Asp Gly Thr Tyr Ser Glu Asn Asn Glu His Trp Gln Tyr Ile 290 295 300 Ser Lys Val Asp Asn Lys Pro Val Glu Gly Leu Tyr Asn Val Gln Gly 305 310 315 320 Asn Leu Gln Tyr Phe Asp Met Ser Thr Gly Asn Gln Val Lys Asn Asp 325 330 335 Ile Arg Ser Val Asp Gly Val Thr Tyr Tyr Phe Asp Lys Asp Ser Gly 340 345 350 Asn Gly Ser Ala Phe Asn Ala Leu Ser Ala Gly Glu Tyr Val Glu Lys 355 360 365 Lys Glu Thr Asp Ala Gln Gly Asn Gln Asn Ser Tyr Trp Thr Tyr Ser 370 375 380 Gly Leu Asp Gly Asn Pro Val Lys Gly Leu Tyr Asp Ile Asn Gly Ser 385 390 395 400 Leu Gln Tyr Phe Asp Glu Lys Asn Gly Ala Gln Leu Lys Gly Gly Thr 405 410 415 Ala Thr Val Asn Gly Val Thr Tyr Tyr Phe Glu Gln Asp Lys Gly Asn 420 425 430 Leu Ile Ser Val Val Asn Ser Val Glu Ser Gly Gln Tyr Lys Ile Asp 435 440 445 Asn Asp Asn Val Tyr Tyr Ile Asp Asn Gln Gly Asn Thr Leu Lys Gly 450 455 460 Leu Tyr Ala Ile Asn Gly Gln Leu Asn Tyr Phe Asp Met Ser Thr Gly 465 470 475 480 Val Gln Leu Lys Gly Ala Ser Glu Asn Ala Asn Gly Val Gly Tyr Tyr 485 490 495 Phe Asp Lys Asp Lys Gly Asn Gly Gln Tyr Gln Tyr Ser Leu Ile Thr 500 505 510 Ser Thr Leu Ala Asn Ala Phe Ser Lys His Asn Ala Ala Asn Asp Tyr 515 520 525 Thr Gln Ser Ser Phe Thr His Thr Val Asp Gly Phe Leu Thr Ala Asp 530 535 540 Thr Trp Tyr Arg Pro Thr Glu Ile Leu Lys Asn Gly Thr Thr Trp Val 545 550 555 560 Ala Ser Thr Ser Gln Asp Leu Arg Pro Met Ile Thr Val Trp Trp Pro 565 570 575 Asn Lys Asn Val Gln Leu Asn Tyr Leu Lys Leu Met Gln Thr Glu Gly 580 585 590 Leu Leu Asp Ser Gly Gln Val Tyr Asp Leu Asn Ser Asp Gln Ala Leu 595 600 605 Leu Asn Gln Ala Ala Gln Thr Val Gln Val Asn Ile Glu Lys Arg Ile 610 615 620 Thr Lys Ala Gly Asn Ser Asp Trp Leu Asn Asp Leu Leu Tyr Asn Ser 625 630 635 640 His Gly Glu Thr Pro Ser Phe Val Lys Gln Gln Ala Ile Trp Asn Ala 645 650 655 Asp Ser Glu Tyr His Gly Gly Trp Phe Gln Gly Gly Tyr Leu Ala Tyr 660 665 670 Arg Asn Ser Asp Leu Thr Pro Tyr Ala Asn Ser Ser Tyr Arg His Tyr 675 680 685 Thr Gly Met Glu Phe Leu Leu Ala Asn Asp Val Asp Asn Ser Asn Pro 690 695 700 Ile Val Gln Ala Glu Asp Leu Asn Trp Leu Tyr Tyr Leu Met Asn Phe 705 710 715 720 Gly Thr Glu Thr Gly Asn Asp Pro Gln Ala Asn Phe Asp Ser Ile Arg 725 730 735 Ile Asp Ala Ile Ser Phe Val Asp Lys Gln Val Ala Lys Lys Ala Tyr 740 745 750 Glu Leu Leu His Asp Met Tyr Gly Leu Ser Ala Ser Asp Ala Val Ala 755 760 765 Asn Lys His Val Ser Ile Val Glu Ala Ser Ala Asp Gln Thr Pro Val 770 775 780 Thr Thr Glu Asn His Asp Ala Leu Ile Glu Ser Tyr Trp Arg Asp Thr 785 790 795 800 Met Lys Asn Ser Leu Ser Lys Asp Ala Ser Ile Asp Ser Ser Ala Gly 805 810 815 Ser Leu Ser Ala Met Ile Asn Asp Gly Asn Val Asp Arg Ala Asn Asp 820 825 830 Ser Thr Thr Glu Ser Ser Ile Phe Pro Asn Tyr Thr Ile Val His Ala 835 840 845 His Asp Lys Asp Ile Gln Asp Ala Val Ser Asn Val Met Lys Ile Val 850 855 860 Asn Asn Asp Pro Ser Ile Ser Leu Asp Gly Phe Thr Met Glu Gln Leu 865 870 875 880 Glu Lys Gly Leu Ser Ala Phe Tyr Ala Asp Gln Arg Ser Ala Val Lys 885 890 895 Gln Tyr Asn Gln Tyr Asn Ile Pro Ser Ala Tyr Ala Val Met Leu Thr 900 905 910 Asn Lys Asp Thr Val Pro Arg Thr Phe Tyr Gly Asp Met Tyr Gln Asp 915 920 925 Asp Gly Gln Tyr Met Ala Asn Lys Ser Leu Tyr Tyr Asp Ala Ile Asp 930 935 940 Thr Met Met Lys Ala Arg Leu Lys Tyr Val Ser Gly Gly Gln Thr Met 945 950 955 960 Ser Val Thr Lys Ile Asn Asn Ala Asn Ser Gln Lys Ser Gly Glu Val 965 970 975 Leu Thr Ser Val Arg Phe Gly Lys Gly Val Met Asp Ala Thr Asp Ala 980 985 990 Gly Ser Ala Glu Ser Arg Thr Gln Gly Ile Gly Val Val Val Ser Asn 995 1000 1005 Ser Ser Gly Leu Gln Leu Asn Asp Asn Asp Lys Ile Val Leu His 1010 1015 1020 Met Gly Ala Ala His Lys Asn Gln Glu Tyr Arg Ala Leu Met Leu 1025 1030 1035 Thr Thr Asn Asp Gly Ile Lys Ser Phe Asn Asn Asp Glu Ala Pro 1040 1045 1050 Ile Asn Tyr Thr Asp Asp Asn Gly Asp Leu Ile Phe Asp Gly His 1055 1060 1065 Asn Ile Asp Gly Gln Glu Asn Thr Ala Ile Arg Gly Tyr Leu Asn 1070 1075 1080 Pro Gln Val Ala Gly Tyr Leu Ala Val Trp Val Pro Thr Gly Ala 1085 1090 1095 Lys Asp Asp Gln Asp Ala Arg Thr Gln Pro Ser Asn Glu Lys Ser 1100 1105 1110 Thr Asp Gly Lys Val Leu His Thr Asn Ala Ala Leu Asp Ser Glu 1115 1120 1125 Leu Ile Tyr Glu Gly Phe Ser Asn Phe Gln Pro Met Pro Thr Thr 1130 1135 1140 Lys Asp Glu Tyr Thr Asn Val Met Ile Ala Lys Asn Ile Asp Leu 1145 1150 1155 Phe Lys Ser Trp Gly Ile Thr Asn Phe Glu Leu Ala Pro Gln Tyr 1160 1165 1170 Arg Ser Ser Asp Gly Lys Asn Ile Asn Asp Arg Phe Ile Asp Ser 1175 1180 1185 Leu Val Gln Asn Gly Tyr Gly Leu Ser Asp Arg Tyr Asp Leu Gly 1190 1195 1200 Phe Glu Thr Pro Thr Lys Tyr Gly Thr Asp Gln Asp Leu Arg Thr 1205 1210 1215 Ala Ile Lys Thr Leu His Gln Ala Gly Met Thr Val Met Ala Asp 1220 1225 1230 Tyr Val Ala Asn Gln Ile Tyr Gly Leu Asn Thr Ser Gln Glu Val 1235 1240 1245 Val Asp Ala Gln Arg Val Asn Ser Asp Asn Asn Ala Val Glu Val 1250 1255 1260 Arg Tyr Gly Gln His Leu Asn Val Val Asn Ser Ile Gly Gly Gly 1265 1270 1275 Glu Tyr Gln Asn Leu Tyr Gly Gly Lys Tyr Leu Glu Ile Leu Asn 1280 1285 1290 Lys Leu Tyr Pro Asp Leu Leu Val Asp Glu Asn Gly Asn Lys Ile 1295 1300 1305 Asp Ile Asp Thr Lys Ile Lys Gln Trp Ser Ala Lys Tyr Leu Asn 1310 1315 1320 Gly Ser Asn Val Thr Gly Leu Gly Met Gly Tyr Val Leu Lys Asp 1325 1330 1335 Trp Ser Asn Gly Gln Tyr Phe Asn Ile Ser Asn Thr Asp Gly Lys 1340 1345 1350 Val Met Leu Pro Glu Gln Leu Val Lys His Met Pro Ala Val Glu 1355 1360 1365 Ile Gly Thr Gln Thr Asn Tyr Thr Ala Tyr Ile Ser Ser Thr Ile 1370 1375 1380 Arg Arg Asp Gly Leu Tyr Asn Asn Met Pro Trp Gly Val Thr Ala 1385 1390 1395 Thr Gly Gln Asp Gly Asn Glu Ile Lys Trp Glu Arg Gln Gly Ser 1400 1405 1410 Thr Ser Asp Tyr Asn His Gln Lys Val Gln Val Asn Arg Gln Tyr 1415 1420 1425 Val Asp Lys Gln Gly Val Val Trp Asn Leu Ile Asn Phe Asp Asp 1430 1435 1440 Lys Asp Leu Trp Val Asp Ser Asn Ala Leu Val Thr Val Asn Phe 1445 1450 1455 Thr Ser Gln Lys Pro Thr Lys His Phe Val Gln Phe Gly Met Arg 1460 1465 1470 Gln Gly Lys Tyr Asp Gly Phe Tyr Leu Ser Ala Pro Tyr Lys Gln 1475 1480 1485 Thr Glu Ser Lys Trp Val Ala Ser Thr Arg Thr His Gln Gly Gln 1490 1495 1500 Leu Leu Glu Val Val Gly Gln Tyr Thr Thr Gly Ser Gly Ser Arg 1505 1510 1515 Lys Val Thr Trp Tyr Leu Val Gly Leu Asp Gly Lys Gln Val Trp 1520 1525 1530 Val Asp Ser Arg Ala Val Gly Thr Asn Phe Ser His Lys Thr Asn 1535 1540 1545 Ile Asn Leu Leu Ile Asn Ser Ala Thr Arg Asn Asp Gly Met Tyr 1550 1555 1560 Leu Asn Ala Pro Tyr Gly Gln Lys Gly Tyr Lys Arg Glu Thr Ser 1565 1570 1575 Ser Arg Phe Tyr Asn Glu Lys Leu Val Thr Val Ser Gln Gln Tyr 1580 1585 1590 Tyr Asp Asn Lys Gly Val Ile Trp Asn Leu Ile Thr Leu Asn Gly 1595 1600 1605 Lys Lys Leu Trp Val Asp Ser Arg Ala Phe Ala Thr Val Ile Asp 1610 1615 1620 Lys Lys Val Asn Gln Ser Leu Tyr Ile Asn Ser Arg Asn Asp Gly 1625 1630 1635 Met Tyr Leu Asn Ala Pro Tyr Arg Ala Gln Gly Ala Lys Arg Tyr 1640 1645 1650 Ala Ser Thr Lys Thr Tyr Thr Gly Gln Arg Val Gln Val Thr Leu 1655 1660 1665 Gln Arg Lys Asp Thr His Gly Val Thr Trp Tyr Leu Thr Lys Val 1670 1675 1680 Asp Ser Lys Gln Leu Trp Val Asp Ser His Ala Phe Ala Pro Thr 1685 1690 1695 Phe Thr Arg Asn Val Ser Leu Asn Val Lys Val Asn Ser Ser Lys 1700 1705 1710 Arg Asn Asp Gly Ile Tyr Leu Asn Ala Pro Tyr Gly Asn Lys Lys 1715 1720 1725 Ala Lys Arg Ile Ala Ser Thr Lys Ala Tyr Asn Gly Lys Arg Val 1730 1735 1740 Lys Ala Ser Lys Glu Tyr Lys Asp Ala Lys Gly Val Thr Trp Tyr 1745 1750 1755 Leu Val Asn Leu Asn Asn Lys Gln Val Trp Ile Asp Lys Arg Ala 1760 1765 1770 Phe 177PRTArtificial Sequenceenzymatic domain 17Ala Asp Phe Val Ala Asn Gln 1 5 1811PRTArtificial SequenceEnzymatic domain 18Ser Met Arg Ile Asp Ala Ile Ser Phe Val Asp 1 5 10 1911PRTArtificial SequenceEnzymatic domain 19His Ile Ser Ile Val Glu Ala Pro Lys Gly Glu 1 5 10 2015PRTArtificial SequenceEnzymatic domain 20Ile Val His Ala His Asp Lys Asp Ile Gln Asp Thr Val Ile His 1 5 10 15 217PRTArtificial SequenceEnzymatic domain 21Ala Asp Tyr Val Ala Asn Gln 1 5 2211PRTArtificial SequenceEnzymatic domain 22Ser Ile Arg Ile Asp Ala Ile Ser Phe Val Asp 1 5 10 2311PRTArtificial SequenceEnzymatic domain 23His Val Ser Ile Val Glu Ala Ser Ala Asp Gln 1 5 10 2415PRTArtificial SequenceEnzymatic domain 24Ile Val His Ala His Asp Lys Asp Ile Gln Asp Ala Val Ser Asn 1 5 10 15

Claims

1. An isolated polypeptide having the ability to form specifically connections of glucosyl units in alpha-1,3 on an acceptor comprising at least one hydroxyl moiety and characterised in that said polypeptide comprises: i) the pattern I of sequence SEQ ID no 1 ii) the pattern II of sequence SEQ ID no 2 iii) the pattern III of sequence SEQ ID no 3 iv) the pattern IV of sequence SEQ ID no 4 or derivatives of one or more of said domains having at least 80% identity with them; wherein said polypeptide furthermore has the aspartic residue (D) in position 5 of the pattern II (SEQ ID no 2), the glutamic acid residue (E) at position 6 of the pattern III (SEQ ID no 3) and the aspartic acid residue (D) in position 6 of the pattern IV (SEQ ID no 4).

2. The isolated polypeptide according to claim 1, characterised in that said polypeptide comprises the sequence SEQ ID no 6, an orthologue, a derivative, or a fragment thereof.

3. The polypeptide according to claim 1, characterised in that said polypeptide comprises or consists of the sequence SEQ ID no 9, an orthologue, a derivative, or a fragment thereof.

4. The polypeptide according to claim 1, characterised in that said orthologue is selected from the group comprising the sequences SEQ ID no 15 and SEQ ID no 17.

5. An isolated polynucleotide encoding a polypeptide according to claim 1, preferably said polynucleotide is defined by the sequence SEQ ID no 10.

6. An expression vector comprising a polynucleotide as defined in claim 5.

7. A transformed host cell including an expression vector as defined in claim 6.

8. A composition comprising at least one polypeptide as defined in claim 1, a polynucleotide encoding said polypeptide, a vector comprising said polynucleotide or a transformed host cell including said vector.

9. A method of producing a polypeptide as defined in any one of claim 1, said method including the steps of: a) inserting a polynucleotide encoding said polypeptide or a vector comprising said polynucleotide into a host cell; b) culturing said cell obtained in step a); and c) extracting the polypeptide from the culture obtained in step b).

10. A process for producing acceptors connected to glucosyl units in alpha 1,3 comprising a rate of connections of such glucosyl units in alpha 1,3 between 1 and 50%, said method comprising the steps of: i) mixing in a reaction medium a polypeptide as defined in claim 1, a substrate of said polypeptide and an acceptor comprising at least one hydroxyl moiety; and ii) incubating said mixture obtained in step i) so as to obtain the connection of glucosyl units in alpha-1,3 on said acceptor.

11. The method according to claim 10, characterised in that the concentrations of substrate and of acceptor are adjusted so to get a connection rate between 35 and 50%.

12. The method according to claim 10, characterised in that the concentrations of substrate and of acceptor are adjusted so to get a connection rate of 20 to 35%.

13. The method according to claim 10, characterised in that the concentrations of substrate and of acceptor are adjusted so to get a connection rate lower than 20%.

14. The method according to claim 1, characterised in that said acceptor connected to glucosyl units in alpha-1,3 is selected from the group of polysaccharides, preferably glucans, including .alpha.-glucans such as dextran, dextrans branched in .alpha.-1,2, alternans, mutans, reuterans, starch, amylopectin, amylose, glycogen and pullulan.

15. The method according to claim 10, characterised in that the substrate is selected from the group comprising .alpha.-D-glucopyranosyl fluoride, p-nitrophenyl .alpha.-D-glucopyranoside, .alpha.-D-glucopyranosyl, .alpha.-L-sorofuranoside, lactulosucrose and sucrose.

16. An acceptor connected to glucosyl units in alpha-1,3 likely to be obtained by the method according to claim 11.

17. A method for the production of acceptors connected to glucosyl units in alpha-1,3, comprising: i) mixing in a reaction medium: a polypeptide as defined in claim 1, of a polynucleotide encoding said polypeptide, of a vector comprising said polynucleotide, of a host cell including said vector and/or a composition comprising said polypeptide, said polynucleotide, said vector, or said host cell, a substrate of said polypeptide, and an acceptor comprising at least one hydroxyl moiety; and ii) incubating said mixture obtained in step i) so as to obtain the connection of glucosyl units in alpha-1,3 on said acceptor.

18. A composition comprising an acceptor connected to glucosyl units in alpha-1,3 as defined in claim 16 as a thickener, emulsifier and/or stabiliser, wherein said composition is a formulation selected from the group consisting of food industrial, cosmetic, agrochemical, petrochemical and pharmaceutical formulations.

19. A method of providing a prebiotic effect comprising administering to a subject in need there of an effective amount of an acceptor connected to glucosyl units in alpha-1,3 as defined in claim 16 as an agent with prebiotic effect.